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IntroductIon
The NHMRC Clinical Trials Centre at the University of Sydney,  
now 25 years old, runs large multicentre investigator-initiated 
clinical trials, undertakes research with national and 
international trial groups, and contributes expertise to trials 
run by others. It also:
•	 takes a lead in proposing new directions for clinical research 
in Australia, particularly research aligned with national policy 
and clinical practice
•	 participates in translational research, from bench to bedside
•	 conducts methodological research in relation to clinical trials
•	 reviews and synthesises evidence from completed trials,  
and is at the forefront of developments in methods,  
such as prospective meta-analysis
•	 supervises postgraduate students in all of these areas
•	 offers postgraduate degrees in clinical trials research
•	 runs short courses to train people for Australian medical 
research.
The CTC also offers health technology and diagnostic test 
assessments, economic analyses, biostatistical design and 
analysis, and automated central randomisation services.
Core funding is provided by the NHMRC, and specific projects  
are funded by government, public and private institutions  
and the pharmaceutical industry. 
The CTC is at two sites in Camperdown in inner Sydney —  
the Medical Foundation Building on parramatta Road and  
Chris o’Brien Lifehouse on Missenden Road.
This report covers the CTC’s achievements for 2013. 
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dIrectors' report
Directors’ report
This year, 2013, marks an important 
milestone for us. It is now over a 
quarter-century since the CTC was 
established. We started operations 
in late 1988, with an initial grant 
of $250 000 and a commitment 
to ongoing funding from the 
NHMRC and provision of facilities 
and services from the University of 
Sydney. By the end of the first full 
year, the CTC had 17 staff and was 
conducting and collaborating in 
large trials in cardiovascular disease 
and cancer, common diseases where 
small improvements make major 
differences to health.
our initial objectives were: to 
promote and help coordinate 
large-scale collaborative clinical trials 
throughout Australia; to provide 
a consultative service for smaller 
clinical trials in design and analysis; 
to provide an educational resource 
to help clinical investigators run their 
own trials, to assist practitioners 
evaluate trial results for clinical 
decision making and to initiate 
appropriate academic courses; and 
to develop and promote research 
in clinical trials methodology and 
research aimed at improving the 
impact of clinical trial results on 
medical practice.
These initial goals still largely reflect 
the philosophy of CTC today. over 
our first 25 years there have been 
many examples of research that 
has changed clinical practice and 
health outcomes.
Highlights of first 25 years
In cardiovascular disease, a long-
standing research focus for us has 
been prevention. Treatments that 
reduce the risk of cardiovascular 
events can benefit many thousands 
of Australians. The LIpID coronary 
disease prevention study, completed 
in 1998, was then the largest trial 
undertaken in Australia. Its results, 
that statin therapy reduced mortality 
in people with average cholesterol 
levels, had a major impact on 
health and on treatment guidelines 
in Australia and elsewhere. Cost-
effectiveness analyses showed that 
the treatment and the trial itself were 
both economically worthwhile, and 
long-term follow-up has shown that 
the treatment is safe. LIpID is also a 
contributor to the ongoing 20-year-
old Cholesterol Treatment Trialists’ 
Collaboration, an international 
prospective meta-analysis 
collaboration, now comprising 
27 trials and 170 000 patients, 
co-founded and co-coordinated by 
the CTC. It has delivered precise and 
convincing evidence on the benefits 
of statin therapy.
The FIELD fenofibrate study, 
1997–2005, was a trial of a potential 
treatment for coronary disease risk, 
but fenofibrate was unexpectedly 
shown to be very effective in 
preventing vascular complications 
of diabetes. In 2013 fenofibrate 
was approved by the Therapeutic 
Goods Administration for diabetic 
retinopathy and has been approved 
in the EU and USA for co-prescription 
with statin therapy for dyslipidaemia.
Both LIpID and FIELD are yielding 
new insights into the risk factors, 
biomarkers and mechanisms of 
cardiovascular disease as we continue 
to follow up patients and analyse 
biological samples in relation to later 
clinical events. FIELD is also exploring 
mechanisms of diabetes affecting 
eye disease, kidney disease and 
foot ulcers.
The CTC has played a significant 
role in the assessment of treatment 
strategies for acute coronary 
syndromes over many years in 
collaboration with international 
trialists of the VIGoUR organisation. 
More recently, in trials of venous 
thrombosis, we showed in ASpIRE 
that aspirin is an inexpensive and 
effective long-term treatment for 
preventing recurrent deep-vein 
thrombosis. The cost of the trial is 
likely to be overtaken within two years 
by national savings in thrombosis 
treatment prevented.
Clinical trials in cancer have 
involved collaboration with many 
cancer cooperative groups—trials 
in prevention, surgical treatment, 
chemotherapy and novel targeted 
therapies. Examples include the 
international IBIS trial with the ANZ 
BCTG where for women at risk, breast 
cancer incidence was reduced by a 
third after five years of tamoxifen, a 
reduction that was maintained over 
10 years of follow-up, the SNAC trial, 
in collaboration with the RACS, of 
minimally invasive sentinel node 
biopsy management instead of 
routine axillary clearance surgery 
for early breast cancer. The newer 
treatment results in better quality  
of life and has now become the 
standard of care.
continued…
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Controlled clinical trials 
are the most scientifically 
valid way to evaluate new 
treatments for patients and 
can also be used to evaluate 
any form of intervention 
aimed at treating or 
preventing disease and 
improving health.
Controlled clinical trials can 
be used not only to identify 
significant, real advances 
in medical care but also to 
identify ineffective therapies 
which may have appeared 
promising in uncontrolled 
studies.
Large-scale clinical trials 
are of important value in 
directing small, but humanly 
worthwhile, improvements 
in treatment.
— John simes, 1988
The promise of individualised 
treatment was realised by the 
international Co.17 trial in 
collaboration with AGITG, a 
biomarker study in which colorectal 
cancer tumours responded to 
cetuximab chemotherapy only if 
they did not have a K-ras mutation. 
International guidelines now 
recommend patients have genetic 
testing so that only susceptible 
tumours are treated, sparing other 
patients an ineffective treatment, 
with potential cost saving of many 
millions of dollars worldwide.
provision for biological and genetic 
studies is an integral part of the 
design of our cancer trials. Similarly, 
most of our trials now include data 
collection for prospectively planned 
cost-effectiveness analyses.
our neonatal trials began in 2001 
with INIS, evaluating the use of 
immunoglobulin to prevent later 
disability or death in newborn infants 
with infection. Immunoglobulin 
has been recommended in clinical 
practice on the basis of some 
evidence, but the INIS trial showed 
conclusively in 2011 that it did not 
make a difference, with the result 
that patients could avoid unnecessary 
treatment and hospitals could save 
its cost.
Notable among our recent 
achievements is the BooST II 
neonatal study, published in 2013, 
which addressed the long-standing 
question of the optimal supplemental 
oxygen target concentration for 
premature infants. The trial’s higher 
target resulted in better short-term 
survival outcomes than a lower 
target for currently used oximeters. 
The impact of this on practice still 
awaits the assessment of long-term 
outcomes with further follow-up and 
confirmation by combined analysis 
of international data from over 
5000 infants in this and similar trials.
We have had leading roles in 
international meta-analysis 
collaborations in cardiovascular 
disease and neonatology for 
many years and other areas more 
recently. As well, we coordinate 
reviews on clinical evidence for 
the Cochrane Collaboration and 
undertake systematic reviews of 
new medical technology for the 
Australian government. Allied to this 
is our important research interest in 
developing methods for evaluating 
clinical tests.
Clinical evidence from systematic 
reviews must be comprehensive 
to minimise bias, so these analyses 
depend on public trial registration. 
The Australian New Zealand Clinical 
Trials Registry based at the CTC is 
the realisation of an early aspiration. 
Launched in 2005, the ANZCTR now 
has about 9000 registered clinical 
trials helping inform ongoing trials 
research and as a resource for reviews 
of trial evidence.
Trial design has diversified since 
1988 as research has sought ways of 
reaching objectives while minimising 
cost and expense. Refinements 
in methods developed here and 
elsewhere improve the way we 
conduct our own trials and are shared 
in the teaching and consultation 
activities of our biostatistics group. 
Building capacity for Australian 
expertise in the design and conduct  
of clinical trials is an important 
activity. The new postgraduate 
program in clinical trials research  
is now well established.
In 2013, we received over $20 million 
in grant funding from public and 
charitable sources. This is the first 
year of our current five-year NHMRC 
program grant for advancing the 
HIstorIcal
John simes, director
anthony Keech,  
deputy director
Wendy Hague, clinical  
trials program director
Kim russell-cooper, 
general manager 
evidence base in national priority 
areas for health, the third such grant 
received by the CTC, but the first for 
a collaborative undertaking (with the 
Boden Institute of obesity, Nutrition, 
Exercise & Eating Disorders). The 
grant is supporting multidisciplinary 
collaborative research focusing on 
diseases with substantial mortality 
and morbidity.
We have had to anticipate and 
respond to changes in the landscape 
of clinical trials over 25 years, 
both global and national. our 
objectives from 1988 have been 
achieved and developed into new 
questions, new methods, new ways 
of conducting trials, and new ways 
of using trial evidence to improve 
health outcomes.
the next 25 years
There are exciting and challenging 
times ahead in clinical trials research. 
There has been an explosion of 
new knowledge about patient and 
disease characteristics based on the 
human genome, with novel targeted 
therapies and more individualised 
therapeutic strategies. Costs of 
health care are continuing to rise and 
regulatory challenges continue. In 
such an environment, clinical trials 
research will be even more important 
in identifying the most effective and 
cost-effective treatments. But more 
efficient trial design and governance 
will be required to ensure this 
system is sustainable and remains 
competitive—with greater use of 
adaptive designs, the need for more 
efficient trial operations embedded in 
the health care system and the ability 
to work effectively with clinical trial 
networks integrated into health care.
After the MJA summit on the 
future of clinical trials in 2012, a 
group of leading Australian clinical 
researchers came together as an 
interim committee to lead formation 
of the Australia Clinical Trials 
Alliance (ACTA), with the purpose 
of cooperating on common issues 
affecting investigator-initiated trials 
in Australia. These issues relate to 
funding, advocacy, identifying gaps 
in research, sharing infrastructure 
(such as biobanks and biostatistical 
expertise), translating research into 
clinical practice and sustaining the 
health system. We are pleased to be 
part of this exciting new venture, 
to be formalised in 2014, designed 
to benefit research, the health care 
system and patients.
on the positive side, methodological 
and technological advances will 
allow us to administer our trials more 
efficiently and potentially better ways 
of doing research can be investigated 
by integrating trials seamlessly with 
electronically recorded clinical care, 
at much lower cost than the current 
model of separate research.
Well-conducted randomised 
controlled trials remain the best way 
of determining the efficacy of new 
treatments. There will be challenges 
in integrating research with basic 
science and clinical care, requiring 
new methods and new partnerships. 
We will be part of the solutions 
by generating new evidence, 
and interpreting, combining and 
applying the evidence to improve 
health outcomes.
ctc executive
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2001
	ctc publishes first 
in a series of studies 
of trade-offs and 
preferences in cancer 
treatment.
	iNis, ctc’s 
first neonatal 
trial, begins in 
collaboration with 
NpeU.
2000
	Biostatistics 
collaboration of 
Australia founded.
1999
	international clinical 
trials symposium, 
‘improving health 
care in the new 
millennium’.
	ViGoUr 
collaboration 
founded with ctc 
as regional centre 
for international 
coronary trials.
1998
	the LipiD trial 
completed and 
published.
	fieLD diabetes trial 
launched by the 
Minister for Health.
	cochrane’s 
prospective  
Meta-Analysis 
Methods Group 
founded and  
based at the ctc.
1996
	the ctc outgrows 
its offices and moves 
to Mallett street in 
camperdown.
1995
	collaboration 
with the NsW 
cooperative 
oncology Group 
(NcoG) on 
investigator-
initiated cancer  
trials.
	the ctc and 
the National 
Breast cancer 
centre initiate 
a collaborative 
review group for 
the cochrane 
collaboration.
1992
	the ctc starts 
collaborating with 
the AGitG.
	ctc establishes 
 and collaborates 
with the Australian 
New Zealand Germ 
cell trials Group 
(ANZ GctG). 
	randomisation of 
over 9000 patients 
in the LipiD trial 
completed.
1991
	the first GUsto trial opens for 
recruitment.
	the first of regular short courses 
on clinical trials presented.
1990
	international tpA/
streptokinase 
mortality trial 
completed.
1988
	CTC sets up offices 
in 5 uncarpeted 
rooms in the 
basement of 
the Edward 
Ford Building, 
University of 
Sydney, with  
two staff.
1996: Mallett street
tIMelIne
1989
 ctc establishes  
statistical and 
randomisation 
centre for the  
ANZ BctG.
 ctc expands to  
10 rooms and  
17 staff.
1993
	first GUsto 
international 
trial closed and 
published, with 
2287 patients in 
Australia and 41 021 
internationally.
	ctc pioneers 
dynamic balanced 
randomisation.
1994
	National cancer 
trials registry is set 
up to disseminate 
information about 
current cancer trials.
 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
dr Michael spence, 
Vice-chancellor, 
university of sydney 
dIrectors' report
2002
	international clinical 
trials symposium.
	ANZGoG 
established.
	5-year NHMrc 
program grant for 
ctc research team 
awarded.
	sNAc trial begun 
after patients’ 
concerns about 
complications 
of breast cancer 
surgery.
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2013
	ctc’s 5-year 
collaboration with 
the Boden institute 
(BioNe) and Macquarie 
University formally 
begins.
	Australian clinical trials 
Alliance established by 
clinical trial leaders to 
advance investigator-
initiated trials research.
	the ctc’s trials group 
move to Lifehouse, a 
new multidisciplinary 
centre for integrated 
cancer care and 
research.
2012
	Aspire shows that aspirin 
is an inexpensive way 
to prevent recurrent 
thrombosis. 
	New evidence from Boost 
ii helps to establish the 
optimum oxygen level for 
newborns.
	cttc results—27 trials, 
174 000 patients—even 
people at low risk benefit 
from lipid-lowering 
treatment.
	Laboratory studies in 
diabetes established at  
the ctc.
	sydney catalyst: the 
translational cancer 
research centre of central 
sydney and regional NsW 
founded: director, John 
simes.
2011
	iNis shows that 
intravenous 
immunoglobulin 
does not benefit 
infants with 
infections.
	Master of clinical 
trials enrols its first 
students.
	MAppiNo shows 
that No does 
not improve 
lung function in 
premature infants.
2010
	Health economics 
group is formally set 
up at the ctc.
2009
	fenofibrate shown to 
reduce amputation in 
type 2 diabetes.
2008
	5-year NHMrc 
program grant for 
ctc research team 
awarded.
	 symposium:  
‘20 years of clinical 
trials’.
	 co.17 investigators 
identify  K-ras gene 
mutation as target 
for cetuximab.
2007
	ANZ GctG and ApUG 
amalgamate to form ANZUp.
	Interpreting and reporting clinical 
trials published by AMpco.
	Communicating prognosis and 
issues surrounding the end 
of life report published and 
becomes the basis for Australian 
guidelines.
	international clinical  
trials symposium.
	cooperative trials Group for 
Neuro-oncology (coGNo) 
established.
	pAris meta-analysis shows 
aspirin prevents pre-eclampsia, 
benefiting mother and baby.
2006
	 Biostatistical meta-
analysis settles the 
controversy about 
radiotherapy after 
mastectomy, finding 
that it is beneficial. 
	 ctc researchers 
devise a strategy 
for evaluating 
diagnostic tests, 
which becomes the 
basis for guidelines 
used by the Medical 
services Advisory 
committee on 
Medicare funding 
for new tests.
2005
	the national 
Australian clinical 
trials registry 
formally established 
at the ctc
	first prospective 
meta-analysis of 
the cttc— 14 trials, 
90 000 patients—
shows conclusively 
that statin drugs 
reduce risk.
	fieLD trial—with 
nearly 10 000 
patients with 
diabetes—
completed and 
published.
2007: Mallett st and MFB
2004
	Australian Lung 
cancer trials Group 
(ALtG)  formed, 
and ctc’s first lung 
cancer trials begin.
2013: lifehouse
 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
International Clinical Trials
Symposium 2007
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oncology research
The CTC’s oncology group of over 40 staff work with 
national cancer collaborative groups to conduct trials 
and associated research that will improve the outcomes 
of people with various cancers. These collaborations 
develop new concepts into working trials. The trials 
result in high-level evidence which is translated into 
standards for cancer treatment and prevention.
The CTC works collaboratively as coordinating centre 
or collaborating sponsor with the Australasian Gastro-
Intestinal Trials Group, the Australia New Zealand 
Gynaecological oncology Group, Australian and 
New Zealand Urogenital and prostate Cancer Trials 
Group, Australasian Lung Cancer Trials Group and the 
Cooperative Trials Group for Neuro-oncology. The 
CTC is the statistical centre for the Australian and New 
Zealand Breast Cancer Trials Group and conducts the 
SNAC breast cancer trials with the Royal Australasian 
College of Surgeons.
Some recent achievements are described in these 
pages.
In 2013 the CTC’s oncology group embarked on ways 
to improve processes working with these collaborators 
and others, including research nurses, data managers 
and pharmacists, international counterparts, such as the 
NCIC CTG in Canada, the Medical Research Council in 
the UK and the European organisation for Research and 
Treatment of Cancer; funders, such as Cancer Australia, 
the NHMRC and the Cancer Institute; and commercial 
partners. The quest for these improvements has come 
in the context of the busy day-to-day running of these 
important cancer trials. The studies address clinical 
questions not only about advancing treatments, but also 
on quality of life, cost issues and translational biological 
substudies.
In its research outcomes, the group and its collaborators 
had a bumper year, publishing 48 journal papers 
and delivering 40 research presentations at major 
international conferences, 18 of these at the American 
Society of Clinical oncology Annual Meeting. Some were 
substudies on biomarkers, quality-of-life or economics 
analyses, some were some early notifications of trials in 
progress, and some were final results of completed trials.
Burcu Vachan, oncology 
program manager, and 
sonia Yip, oncology senior 
translational research fellow  
and manager
Martin stockler, co-director of 
the ctc’s oncology trials
IMproVIng qualItY oF lIFe and surVIVal For people WItH cancer
DANieLLe ferrAro
the Kristian Anderson Award, 
which provides funding to support 
a clinician to research an aspect of 
personalised medicine in the area 
of bowel cancer, was presented to 
Dr Danielle ferraro, clinical research 
fellow for the gastrointestinal and 
lung trial groups.
she is investigating use of cetuximab 
and panitumumab in colorectal 
cancers. these drugs are effective 
for only some patients’ tumours. 
Dr ferraro aims to produce a test 
that gives clinicians more accurate 
information about which patients 
would benefit from these drugs, 
which will spare other patients their 
side-effects.
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Gastrointestinal cancer 
(AGitG)
The CTC has been conducting 
trials with the Australasian Gastro-
Intestinal Trials Group since the early 
1990s. In that time the collaboration 
has published nearly 80 articles in 
scholarly journals and presented over 
130 study findings at national and 
international conferences.
In 2013, the group presented final 
results of ATTAX3, an Australian trial 
of adding panitumumab to standard 
chemotherapy as a treatment 
for advanced oesophagogastric 
cancer, a cancer associated with 
poor prognosis. panitumumab is 
a human monoclonal antibody 
targeting the epidermal growth 
factor receptor. It has had some 
success as a treatment for colorectal 
cancer, but this trial showed that the 
treatment did not benefit patients 
with oesophagogastric cancer. The 
results of the LAp07 pancreatic cancer 
trial were also presented, similarly 
showing that radiotherapy in addition 
to standard chemotherapy did not 
improve outcomes. Both these trials 
will spare future patients ineffective 
additional treatments as the search 
for better treatments goes on.
A new trial for 2013, ASCoLT, is 
testing the efficacy of aspirin in 
reducing recurrence in people 
who have already had surgery and 
treatment for colorectal cancer. 
Aspirin is safe and inexpensive and 
appears to have anticancer properties. 
The study will also measure survival 
and find out the characteristics of 
patients who benefit most.
At the other end of the trial lifecycle is 
the MAX colorectal cancer trial, which 
was the first AGITG-CTC international 
trial, completed in 2009. MAX 
was part of a recent meta-analysis 
of 7 trials totalling 3178 patients 
examining the effect of adding 
bevacizumab, a monoclonal antibody, 
to chemotherapy treatment.181 
The new analysis was large enough 
to show the effects in subgroups, 
including 426 patients aged 75 years 
or over, and confirmed that this 
group did benefit from bevacizumab 
treatment. This finding is important 
because elderly patients have been 
underrepresented in clinical trials. 
Tumour tissue from MAX trial 
patients is being analysed in relation 
to biomarkers for prognosis and 
prediction of how treatment affects 
individual patients (p. 15).112
CANCER GRoUpS
professor  John Zalcberg, 
chair of  agItg
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Lung cancer (ALtG)
The Australasian Lung Cancer Trials 
Group was formed in 2004, the same 
year the first of its trials with the 
CTC were initiated. Trials have been 
conducted in non-small-cell lung 
cancer and mesothelioma.
Mesothelioma is a form of lung 
cancer caused by exposure to asbestos 
and is usually only detected when it is 
advanced. New drugs for treatment 
after initial chemotherapy are badly 
needed. A new agent, BNC105p, 
which targets the blood vessels in 
tumours, suppressing tumour growth, 
was recently tested for efficacy and 
safety by ALTG investigators.102 
Unfortunately, it did not live up to 
its promise. It was not effective on 
its own, but may act to improve 
the delivery of other treatment, so 
future investigations will examine 
combinations with chemotherapy 
drugs.
CANCER GRoUpS
Another drug that acts against 
blood vessel growth, cediranib, was 
investigated in an ALTG collaborative 
trial with the National Cancer 
Institute of Canada Clinical Trials 
Group.83 This study found that the 
drug did not improve the survival 
of people with non-small-cell lung 
cancer.
Recent studies on patients’ 
preferences in trade-offs between 
survival and chemotherapy treatment 
in lung cancer have been published or 
presented at international meetings 
(p. 14).88,93
Gynaecological cancer 
(ANZGoG)
Since 2000, the Australia New 
Zealand Gynaecological oncology 
Group, whose trials are coordinated 
at the CTC, has been the lead group 
for trials in ovarian cancer, cervical 
cancer, and cancer of the uterus, vulva 
and vagina. The group aims to initiate 
and conduct trials covering surgery, 
drug treatments and radiation, as well 
as biological research and quality-
of-life studies. Most importantly, 
research questions reflect the needs of 
patients. The group also emphasises 
engagement of patients and their 
families with the research process.
The ANZGoG-CTC Symptom 
Benefit trial is an open international 
quality-of-life study, which is 
measuring subjective improvement 
as well as the tumour response 
in women who have palliative Kate sawkins, operations associate oncology program manager  for altg and cogno
associate professor 
paul Mitchell, 
president of altg
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IMproVIng qualItY oF lIFe and surVIVal For people WItH cancer
anne long, clinical research fellow, 
and professor Ian davis, chair of anZup
chemotherapy after ineffective 
platinum chemotherapy for advanced 
ovarian cancer. The Australian 
investigators recently published a 
substudy of the relationships among 
expectations, hope, and depression 
in the participants. They found that 
if women’s hopes were not fulfilled, 
they were more likely to become 
depressed. This has implications for 
the way that clinicians communicate 
with these patients.132
The collaboration undertook a 
substudy of the Australian ovarian 
Cancer Study, looking at physical 
symptoms, coping styles and quality 
of life in the last year of life of women 
whose cancer had recurred.111 The 
findings are important for patients 
and their doctors who have to make 
decisions about treatment and 
supportive care at the end of life.
Urogenital cancer (ANZUp)
The CTC is coordinating centre for 
the trials of the Australian and New 
Zealand Urogenital and prostate 
Cancer Trials Group, formed 5 years 
ago to meet a need to improve 
treatment of bladder, kidney, 
testicular and prostate cancers 
through clinical trials research.
The successful completion in 2013 of 
Accelerated BEp, the pilot trial of an 
accelerated chemotherapy regimen 
for testicular cancer, showed that 
the treatment was safe, feasible and 
active, leading the way for a new 
large international trial to obtain 
high-level evidence on definitive 
treatment for men with testicular 
cancer, particularly those at high risk. 
This trial, which will be led by ANZUp 
and the CTC, is currently being 
initiated. An Australia-wide survey of 
current patterns of management of 
this disease by medical oncologists53 
indicated a need for evidence-based 
dr alison Brand, chair of anZgog
guidelines, expected to be the end 
result of the new trial.
An essential precursor to any new 
clinical trial is a thorough review of 
the current evidence on the clinical 
question. This is the case for a new 
phase 3 trial of a treatment regimen 
for bladder cancer, BCG+MMC, 
expected to open in 2014. CTC 
and ANZUp researchers undertook 
a systematic review and meta-
analysis of available evidence on 
the effect of intravesical (that is, 
introduced directly into the bladder) 
chemotherapy added to standard 
therapy. This review recommended 
that a further trial was warranted 
but that only some stages of 
bladder cancer were responsive to 
the treatment. The treatment will 
now be tested in the new trial, with 
participation in the trial limited to 
patients who have these specific 
tumours.
CANCER GRoUpS
tumours of the brain and nervous system (coGNo)
diana Winter, 
caBaret data manager, and 
ann livingstone, associate 
oncology program manager, 
cogno and altg
professor Mark rosenthal, 
chair of the cogno 
scientific advisory 
committee
oncology, both found variations in 
aspects of treatment, pointing to 
specific needs for future clinical trials 
on treatment strategies.
The CABARET trial is an ongoing 
study of treatment for glioblastoma, 
an aggressive brain cancer. 
Glioblastoma that recurs after 
initial treatment currently does 
not have standard treatment. The 
trial investigated bevacizumab, a 
monoclonal antibody that inhibits 
the growth of new blood vessels in 
tumours, with or without carboplatin 
chemotherapy. The preliminary 
results, that adding carboplatin to 
bevacizumab did not result in clinical 
benefit compared with bevacizumab 
alone, were presented at the 
meeting of the American Society 
of Clinical oncology. This study is 
also providing data for substudies 
and exploratory analyses, including 
the benefits of continuing versus 
stopping bevacizumab after disease 
progression, and a validation of 
the criteria for assessing tumour 
response.
The Cooperative Trials Group for 
Neuro-oncology (CoGNo) is 
a relatively young collaborative 
investigator group. It was established 
in 2007 in response to a need for a 
coordinated, structured approach 
to the management of large-scale, 
multicentre brain cancer trials in 
Australia.
CoGNo’s annual scientific meeting 
in 2013 was its first stand-alone 
conference. This annual event is 
a forum where current work by 
local and international research 
leaders is presented and where 
ideas for new trials are conceived. 
So far there have been few trials 
in this area. Foundation work by 
CoGNo researchers has included 
determining the current status of 
treatment in Australia. The first 
Australia-wide study of patterns of 
care for glioblastoma, published in 
the Asia-Pacific Journal of Clinical 
Oncology,28 and another study on 
care for medulloblastoma, presented 
at the American Society of Clinical 
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IMproVIng qualItY oF lIFe and surVIVal For people WItH cancer
Breast cancer
The CTC is the statistical and 
randomisation centre for the Australia 
and New Zealand Breast Cancer 
Trials Group, doing methodological 
research, statistical design of new 
studies, management of quality of 
life and cost-effectiveness protocols, 
systematic reviews of data quality and 
analyses of current trials.
CTC statisticians and oncologists 
recently published data from an 
early ANZ BCTG trial to test trade-offs in quality of life and survival with 
two different chemotherapy regimens for advanced breast cancer.85 The 
investigators assessed patients’ quality of life while on chemotherapy and 
also assessed side-effects associated with treatments. They found that 
the more toxic but also more effective regimen was associated with more 
improvement in progression-free survival adjusted for quality-of-life score 
than the lesser toxic but also less effective therapy.
The methods used, of weighting quality-of-life assessment by patients 
to obtain global scores and integrating weighted scores with survival 
outcomes, were methods initially developed by CTC statisticians and 
their colleagues in the past. When applied to this breast cancer trial, the 
methods provided a complete picture of the balance of benefit and harm, 
and are recommended for use in future trials where trade-offs of toxicity 
with tumour response and survival exist.
seNtiNeL NoDe 
Biopsy VersUs 
AxiLLAry 
cLeArANce 
(sNAc)
sNAc was a trial to compare the 
outcomes of sentinel lymph node 
biopsy compared with axillary node 
clearance in early breast cancer. 
Axillary node clearance, a more 
invasive procedure, often results in 
arm swelling (lymphoedema).
sNAc was notable in that it arose 
directly from concerns of patients, 
who felt that lymphoedema was 
underestimated by the medical 
profession. At the National Breast 
cancer conference in 1998, 
those present recommended that 
researchers collect and report 
evidence on lyphoedema and the 
different surgical options for early 
breast cancer.
sNAc began in 2001 as a 
collaboration between the royal 
Australiasian college of surgeons 
and the ctc with funding from 
the Medical Benefits fund and the 
Department of Health and Ageing. 
it was completed in 2005 after 
very rapid recruitment, which was 
partly attributed to the interest of 
consumers in this question.
the investigators reported that, after 
one year, women who did not have 
an axillary clearance had less arm 
swelling. Arm swelling increased over 
time. patients are still being followed 
up for lymphoedema and other 
effects of surgery, and data from the 
trial will contribute to a prospective 
meta-analysis of recurrence of breast 
cancer after the trial treatments.
chee lee, clinical lead in 
oncology research
sarah chinchen, 
operations 
associate oncology 
program manager 
and mentor.
HIstorIcal
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cancer studies that address patients’ circumstances and 
psychological needs
Most clinical trials in cancer investigate novel treatment regimens to maximise 
survival and quality of life. However, most trials also generate data that 
can be analysed to find the best ways of meeting the psychosocial needs of 
patients. This is used in studies of, for example, how oncologists can predict 
and communicate likely survival in the context of uncertainty, and how much 
treatment individual patients will freely endure for survival.
survival and prognosis
people with advanced cancer often want information about their expected 
survival time, and those wanting information prefer to receive estimates for the 
possible worst-case, typical and best-case scenarios rather than receive a single 
number estimate of median survival.82  It is difficult for oncologists to estimate 
and explain survival time in a meaningful way. In a study recently published in 
the Journal of Clinical Oncology, CTC researchers and their colleagues examined 
the accuracy and usefulness of oncologists’ estimates of survival time for 
patients with mixed incurable cancers.81 Although the actual estimates were 
not accurate, they were useful and accurate as a basis for estimating worst-
case, typical and best-case scenarios. For patients requesting information on 
their likely survival time, presenting this information as three scenarios should 
improve patient understanding and help with decision making and planning.
preference studies
The CTC and its collaborative groups have a reputation for useful observational 
studies investigating attitudes to chemotherapy from the patient’s point 
of view—that is, asking patients to articulate the increase in survival that 
would make their chemotherapy worthwhile.88 Two of these studies by ALTG 
(p. 10) and the CTC, one eliciting patients’ preferences and the other eliciting 
clinicians’ preferences, were presented at the World Conference on Lung 
Cancer in october 2013. The patients, who had non-small-cell lung cancer, 
indicated that chemotherapy was worthwhile for moderate improvements in 
survival. Clinicians’ preferences were similar but less varied. These investigators 
also sought to find out patients’ preferred and actual levels of involvement 
in decision making. Their preferences were varied but stable, prompting the 
conclusion that clinicians should talk to patients and consider their preferences 
for involvement in decision making when discussing chemotherapy treatment 
for lung cancer.
For advanced ovarian cancer, the standard treatment is infusion of 
chemotherapy drugs. However, in terms of acting on the tumour, delivering 
chemotherapy directly into the abdomen would be ideal because it exposes 
the tumour to a higher concentration of drugs. This is not commonly done in 
Australia because of concerns about side-effects and inconvenience. ANZGoG 
and CTC investigators (p. 10) have completed a trial to determine the feasibility 
of this method, looking at survival, complications, quality-of-life measures 
and patients’ preferences in trade-offs between survival and quality of life.8 
If the major purpose of the 
trial is to help decide which 
treatment strategy is more 
likely to benefit the patient, 
then it is important to take 
into account the advantages 
and disadvantages of each 
of the therapies from the 
patient’s perspective…. For 
example, a treatment which 
offers an additional 3 months 
survival may not be preferred 
if it is at the expense of 
considerable side-effects  
from therapy.
— John simes, 
Statistics in Medicine, 1985
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patients judged treatment worthwhile for a survival improvement of months, 
but their responses were tempered by the greater toxicity and inconvenience of 
this method. preference studies such as this are recommended in all treatment 
trials, because they can help determine the acceptability and likely uptake of the 
regimens.
translational research in cancer
Translational research aims to integrate all phases of medical research, from 
scientific innovation in the laboratory through various phases of clinical trials 
to ways of implementing research findings in clinical practice. This integration 
speeds the long pathway between scientific discoveries and their practical use to 
improve the outcomes for patients.
The CTC has a close relationship with Sydney Catalyst: the Translational Cancer 
Research Centre of Central Sydney and Regional NSW. This consortium brings 
together teams of clinicians and researchers from more than 20 member 
organisations. Its offices and staff are co-located with the CTC and CTC director 
John Simes is founding and current program director of Sydney Catalyst.
During 2013 Sydney Catalyst celebrated important milestones, including a 
growth in membership (from just over 200 in 2012 to more than 330 at the 
end of 2013), a highly successful International Translational Cancer Research 
Symposium in May with over 120 participants, more than 500 publications, 
close to $45 million in competitive funding from a subset of members and good 
progress against important flagship projects in lung and pancreatic cancers.
clinical trials and translational research
patients enrolled in clinical trials receive the best treatments for their particular 
disease, but individual patients may respond differently depending on the 
individual characteristics of their tumours, including the proteins expressed 
by the DNA in the tumour. Drugs that act against protein expression, such as 
monoclonal antibodies, are used in cancer treatment, but some patients may 
benefit from the treatment and some may not. There are many unknowns in the 
use of these promising anticancer agents.
Most of the CTC’s clinical trials include analysis of tumour tissue and blood 
samples in laboratory studies that compare the tumour and blood characteristics 
with the individual response to treatment. Ultimately, this information should 
improve treatment planning, allowing clinicians to test patients and identify who 
would benefit from particular drugs.
Detecting such tissue and blood biomarkers to predict a patient’s response to a 
therapy is a focus of the laboratory studies associated with the CTC’s clinical trials.
For example, the monoclonal antibody tested in the completed MAX trial, 
bevacizumab, which acts against vascular endothelial growth factor, is now 
included in initial therapy regimens for metastatic colorectal cancer because it 
improves patient outcomes. It is known to bind to and inactivate one kind of 
vascular endothelial growth factor, but the drug’s action against its targets is 
complex and so far survival benefits have been modest. Current research focuses 
on examining tumour tissue for biomarker subtypes in the light of known patient 
responses to bevacizumab.112
GeNoMic cANcer cLiNicAL 
triAL iNitiAtiVe (Gccti)
the Gccti is a 3-year program to 
support the national cooperative 
cancer clinical trials groups, 
including those described in these 
pages, in developing trial protocols 
testing new drugs whose molecular 
target may be common to different 
cancer sites. the process will cover 
generating and prioritising ideas, 
developing these concepts and 
making applications for national and 
international grants.
the Gccti aims to develop at least 
one new protocol per year. in 2013 
the group held the first of its annual 
concept workshops.
the program is funded by cancer 
Australia and managed by the 
ctc, with chief investigator Martin 
stockler, clinical leads chee Lee 
and Katrin sjoquist, and senior 
translational fellow sonia yip, in 
partnership with independent 
consulting group Zest Health 
strategies. 
Katrin sjoquist, clinical lead  
for gcctI, and research student 
aflah roohullah
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cardiovascular research
lIpId had a large investigator group, seen 
here at their final meeting in palm desert, 
usa in 1998
LipiD
Cardiovascular disease is the underlying cause of more than 1 in 5 
deaths in Australia. Research evidence in this area, when translated into 
prevention and treatment, can therefore make a big difference to health. 
In recent years, the death rate has been declining.
The CTC aims to undertake trials aimed at improving treatments, 
evaluating best available therapies and addressing areas where 
individuals at high risk are currently untreated. The CTC has been 
responsible for coordinating nine large cardiovascular trials in Australia. 
Seven of these were international collaborative trials of treatments for 
acute coronary syndromes, and two, LIpID and FIELD, were prevention 
trials designed and implemented in Australia and New Zealand. In total, 
the CTC randomised 26 565 of the patients enrolled these trials.
With improvements in methods and interpretation, meta-analysis of the 
results of all trials with the same entry criteria and measured outcomes 
have become an alternative to large randomised trials. If meta-analyses 
are prospectively planned, they provide the same strength of evidence of 
a large trial but are easier to initiate and manage.
The CTC co-coordinates the Cholesterol Treatment Trialists’ 
Collaboration, a prospective meta-analysis group set up in the early 
1990s by the CTC and the Clinical Trial Service Unit at oxford. The group 
is now analysing data from 27 cholesterol-lowering trials totalling nearly 
170 000 people. 
Biomarkers of cardiovascular risk in the LipiD study
HIstorIcal
The Long-Term Intervention with 
pravastatin in Ischaemic Disease 
(LIpID) study showed that statin 
treatment reduced the risk of a 
second or further coronary event 
in people with heart disease. Blood 
samples collected over the first 6 
years of the trial are being analysed 
to shed light on how biomarkers are 
related to heart disease risk.
For example, it has been thought 
that statins reduce cardiovascular 
risk by reducing LDL cholesterol, but 
more recently that other mechanisms 
are also important. The LIpID study 
investigators assessed Lp-pLA2, 
an enzyme found in blood vessel 
plaque. They found that pravastatin 
treatment reduced Lp-pLA2 levels, 
and this accounted for much of 
the reduction in subsequent heart 
attacks.159
other analyses showed that 
lipoprotein a98 and troponin160 levels 
were significant risk factors for future 
cardiovascular events.
More of these biomarker analyses 
are ongoing or yet to come. The 
LIpID Australian and New Zealand 
investigators are collaborating with 
scientists from Germany, Sweden and 
the United States.
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LipiD: AN eArLy ctc LArGe-scALe MULticeNtre triAL 
the LipiD trial of cholesterol-lowering treatment with pravastatin was a major achievement of the ctc in its early days. the trial 
recruited patients who had recently had a coronary event but had normal cholesterol levels. over 9000 patients from 87 hospitals 
in Australia and New Zealand were randomised between 1990 and 1992 and then followed up for 6 years. 
the treatment significantly and cost-effectively reduced mortality and major cardiovascular events. overall mortality was reduced 
by 23% and coronary heart disease death by 24%. clinical evidence from LipiD enabled subsidy for pravastatin treatment through 
the pharmaceutical Benefits scheme in 1999 and change in the Australian treatment guidelines.
Blood samples were collected from patients at entry to the trial and during the trial. research is now focusing on what the blood 
samples can tell us about coronary heart disease.
the LipiD group is also analysing data on deaths and cancers in the patients over 16 years of follow-up.
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patients from the completed FIELD 
trial are still being followed up 
through regular questionnaires and 
data linkage.
The investigators are also using blood 
samples taken during the trial and 
its follow-up to study the effects and 
mechanisms of fenofibrate treatment 
and to determine biological and 
genetic markers of the risk of various 
manifestations of cardiovascular 
disease and diabetes complications.
Action of fenofibrate in mice
Fenofibrate was originally described a 
as ppAR-α agonist, acting on blood 
lipids to reduce the risk of vascular 
diseases. A substudy of the FIELD 
trial in 2010 unexpectedly showed 
that fenofibrate dramatically reduced 
the risk of amputation, leading the 
investigators to look for further 
mechanisms of action of fenofibrate. 
fenofibrate intervention and event Lowering in Diabetes (fieLD)
preVentIng cardIoVascular dIsease
Since then animal and laboratory 
studies to tease out this effect have 
been done. In a study by Rajamani 
and colleagues, the blood flow in 
the hind limbs of diabetic mice was 
reduced in a simulation of blood 
vessel damage. Then fenofibrate 
treatment ameliorated the effect, 
restoring blood to the extremities 
and allowing the paws to move. 
Associated tissue studies revealed that 
fenofibrate appeared to promote new 
blood vessel formation. Molecular 
pathway studies are ongoing.
High bilirubin equals low 
amputation risk
people with diabetes have a higher-
than-normal risk of amputation 
of toes or feet due to blood vessel 
disease. As an early step in finding 
a way of reducing this risk, FIELD 
investigators tested bilirubin in the 
blood as a possible predictive marker. 
Bilirubin is known to have antioxidant 
A LArGe iNterNAtioNAL triAL to reDUce risK of cArDioVAscULAr coMpLicAtioNs of DiABetes
fieLD was a double-blind placebo-controlled trial of the use 
of fenofibrate to reduce the risk of coronary heart disease in 
people with type 2 diabetes, chaired by ctc deputy director, 
Anthony Keech. the trial was conducted in Australia, New 
Zealand and finland. it was initiated in the late 1990s, began 
recruiting patients in early 1998, and its five-year follow-up was 
completed in october 2005.
A feature of the trial was that its wide entry criteria allowed the 
results to be generalised to a population of typical patients with 
diabetes consulting general practitioners.
the main results showed that fenofibrate did not significantly 
reduce risk of myocardial infarction or death from coronary 
disease, but it did have a significant effect on other 
cardiovascular disorders, notably amputations and the need for 
laser treatment for retinal disease. the finding that fenofibrate 
appeared to prevent microvascular disease, led to new directions 
of research examining the reasons and mechanisms. on the 
basis of these results (and another study), the Australian 
therapeutic Goods Administration approved fenofibrate for 
diabetic retinopathy in December.
Also, during the trial, evidence emerged from other trials around 
the world that statin therapy reduced the risk of cardiovascular 
disease, and many patients, especially in the active fenofibrate 
group, started taking statins as well as their study drug. this 
was considered to cause potential confounding likely to result 
in underestimation of the benefit of fenofibrate treatment. 
ctc researchers developed a novel statistical method to adjust 
treatment effects for use of other medication. the approach can 
be applied to other long-term trials where differential changes in 
usual care between treatment arms occur unexpectedly.
and anti-inflammatory properties 
which may protect the blood vessels. 
The investigators found a significant 
association between lower bilirubin 
levels and higher risk, raising the 
hypothesis that bilirubin may protect 
against amputation.26
is HDL cholesterol linked to poor 
glucose control in diabetes?
HDL (good) cholesterol is often low in 
people with type 2 diabetes and may 
be low years before diabetes becomes 
apparent. The FIELD team are 
investigating whether HDL biology 
contributes to the development and 
progression of type 2 diabetes. Initial 
results, presented at the meeting of 
the Cardiac Society of Australia and 
New Zealand,suggest that levels of 
HDL cholesterol and its components 
are directly related to slowing diabetes 
progression, a finding that is being 
further explored for full publication in 
the near future.
HIstorIcal
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Diabetes and vascular disease
Type 2 diabetes is an increasing 
health burden in Australia and 
worldwide. often, the diagnosis of 
type 2 diabetes is made only when 
symptoms occur, after many years of 
high blood glucose. Type 1 diabetes, 
which often presents in childhood 
and requires daily insulin injections, 
affects over 122 000 Australians and is 
increasing in incidence. Both forms of 
diabetes can irreversibly damage the 
kidneys, blood vessels, nerves, heart 
and eyes. Investigators at the CTC 
and their clinical co-workers continue 
to seek ways to predict and prevent 
diabetes, to reduce the destructive 
consequences of diabetes and to use 
technology to improve diabetes care. 
The international FIELD trial, 1997–
2005, is still providing data for blood 
marker and other substudies. FIELD is 
now joined by REMoVAL, which aims 
to test the use of metformin, a type 2 
diabetes medication, for preventing 
blood vessel damage in adults with 
type 1 diabetes.
Many research efforts are focusing 
on earlier diagnosis and prevention 
of diabetes and its complications. At 
the CTC, these range from laboratory-
based cell and animal model studies 
to the new T4DM and FAME1-EYE 
clinical trials.
reMoVAL:  
a new trial of an old drug
Metformin is a common, inexpensive 
and usually well-tolerated drug 
used for blood glucose control in 
type 2 diabetes. It also reduces 
cardiovascular complications and 
reduces insulin resistance, which can 
also be a feature of type 1 diabetes. 
A new international type 1 diabetes 
trial is being conducted to discover 
whether metformin can slow or 
prevent atherosclerosis. During 3 
years of metformin treatment or 
placebo, participants are having 
scans to assess changes in their blood 
vessels and heart.
testosterone for the prevention 
of diabetes mellitus (t4DM)
Low testosterone levels are often 
associated with lower motivation to 
exercise, lower muscle mass and with 
a higher risk of type 2 diabetes. The 
T4DM trial is recruiting 1500 middle-
aged men who have low testosterone 
levels and prediabetes, that is, higher 
than normal blood glucose levels, 
to see whether treating them with 
a weight-loss diet and testosterone 
supplements over 2 years can prevent 
progression to full-blown diabetes.
The men are initially screened on the 
basis of their waist circumference and 
then screened again by blood tests for 
testosterone levels and blood glucose. 
Investigators expect to screen 24 000 
Australian men during recruitment. 
The study design and progress to date 
were presented in 2013 at the World 
Diabetes Conference.
fenofibrate and Microvascular 
events (fAMe1-eye)
Irreversible vision loss is a most feared 
complication of diabetes. The FIELD 
type 2 diabetes trial showed that the 
lipid-modifying drug fenofibrate was 
effective against vision-threatening 
diabetic damage to retinal blood 
vessels in the eye. Laboratory studies 
have backed up these findings and 
shown how the drug works. In a study 
published in 2013, it was shown 
that in mice with type 1 diabetes, 
fenofibrate, administered orally or by 
injection, reduced inflammation and 
leakage from the blood vessels in the 
eye.29
Now a major new trial is investigating 
the use of fenofibrate tablets to 
protect the vision of people with type 
1 diabetes who have early diabetic 
retinal damage. Investigators from 
the CTC, the University of Melbourne 
and Westmead Hospital in Sydney 
are collaborating in the FAME1-EYE 
study, a 3-year double-blind, placebo-
controlled trial of daily fenofibrate for 
450 adults with type 1 diabetes
continued…
Karen Bracken, t4dM trial project manager 
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Should the results prove positive, 
an existing, low-cost, well-tolerated 
treatment to reduce the personal 
and economic burden of the 
complications of type 1 diabetes could 
rapidly be translated into clinical 
practice world-wide.
Using technology to improve 
health care in remote areas
The diabetes group has extended its 
research into telehealth, a model of 
patient care that can improve health 
care access, particularly in rural and 
remote areas. Whereas in cities the 
death rate from diabetes-related 
causes has dropped in recent years, 
it has remained stable at about 45 
deaths per 100 000 among people 
living in regional and remote 
areas. Type 2 diabetes is especially 
prevalent among people in Aboriginal 
communities, and retinal eye disease 
is a common complication.
The Telehealth Eye and Associated 
Medical Services (TEAMSnet) 
collaboration has embarked on 
a program to use internet and 
mobile technologies to provide 
eye examinations and coordinated 
diabetes and heart care to indigenous 
Australian people. patients and 
consumers may be ahead of health 
care professionals in the use of 
new technology.18 The diabetes 
study is recruiting participants 
from 3 Aboriginal communities 
in the Northern Territory. The 
research group will monitor and 
analyse images of the retina via 
telecommunication channels and will 
also evaluate education, coordination 
of medical care, patient preferences 
and clinical decision making. The 
group has already obtained valuable 
insights into telehealth: care delivered 
by a virtual team can optimise health 
outcomes, telehealth supports shared 
decision making . These findings were 
presented at the 2013 meeting of the 
Australian Diabetes Society.
Laboratory research
rNA-based analysis for 
prediction of islet death
Blood glucose levels are normally 
tightly regulated by insulin released 
from beta cells in the pancreas. 
Insulin lowers blood glucose levels 
and enables the body’s cells to utilise 
and store the energy in glucose. By 
the time type 1 diabetes is diagnosed, 
over two-thirds of the pancreatic beta 
cells have been killed by inflammation 
and immune attack, usually over 
several years. Beta cell death also 
contributes to the progression of type 
2 diabetes glucose-control treatment 
from diet and exercise alone, to 
tablets, to insulin injections.
RApID is a laboratory study searching 
for biomarkers that may allow 
diabetes to be predicted before the 
damage is done and to monitor the 
efficiency of protective treatments. 
A class of RNA (genetic) molecules 
(microRNAs) regulating gene 
expression are being investigated 
as potential markers of beta cell 
damage. The RApID investigators 
have developed a method to identify 
microRNAs as markers of pancreatic 
cell death.40 They are continuing to 
analyse levels of various microRNAs 
in the blood, with the eventual goal 
of a blood test that could detect 
loss of pancreatic cells before the 
clinical onset of diabetes or monitor 
treatments to slow down damage to 
the pancreas.
andrzej Januszewski, diabetes laboratory research fellow, with alicia Jenkins,  
professor of diabetes molecular medicine and telehealth
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a Better Future For neWBorns
the NeoproM meta-analysis
Although oxygen treatment for premature babies 
has been in use for 60 years, the best level of 
oxygen to prevent death and disability is still not 
known.
Different levels of oxygen, even though they 
may differ by only a few percentage points, have 
different benefits and harms. Too much oxygen 
may cause vision loss; too little oxygen may lead 
to death from lung disease. Although several 
trials have been completed, testing this question 
properly requires at least 5000 participants, 
which is beyond the resources of any single trial 
group. Instead, five trial groups are cooperating 
in a prospective meta-analysis, called NeoproM, 
started in 2003 and now nearing completion. 
The CTC’s BooST II trial is following up 1055 
infants born very prematurely in Australia and New Zealand over two years. 
In BooST II they were randomly allocated to 85–89% or 91–95% oxygen 
saturation.10 Recruitment to the trial was stopped after an analysis of data from 
BooST II and other NeoproM trials showed better survival up to 36 weeks in 
the group that received the higher oxygenation level. This was published in 
the New England Journal of Medicine.10 Recommendations on the best range 
of oxygen saturation await a full 2 years of follow-up and the NeoproM study 
analysis.
lisa askie, investigator 
for neonatal studies 
and head of the ctc’s 
systematic reviews 
and health technology 
assessment group
clinical trials and meta-analyses  
in neonatology
William tarnow-Mordi (foreground), investigator for Boost II  
with alpana ghadge, manager of Boost II
For decades, the optimum 
range of oxygenation was, 
and remains to this day, 
unknown. Unfortunately, 
the uncertainty continues 
and  the question of what 
is the optimal oxygen 
saturation range for preterm 
infants is a moving target. …
The oxygen story 
highlights the potential 
for unanticipated, adverse 
consequences when clinical 
practices are changed only 
on the basis of anecdotal, 
observational and 
nonrandomised evidence.2
— Lisa Askie, 
Current Opinion in 
Pediatrics
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Australian placental transfusion study (Apts)
ApTS is an open multicentre CTC trial which will eventually have 1600 
participants—babies born more than 10 weeks early. 
It will determine whether a 60-second delay in clamping and cutting the 
cord can improve the baby’s blood flow to the brain and gut, reduce the 
need for donor blood, and reduce rates of infection, retinopathy, poor 
growth, death and disability in babies born more than 10 weeks early.
Lactoferrin infant feeding trial (Lift)
Does lactoferrin reduce mortality and morbidity in very low birth weight 
infants?
Exciting recent evidence suggests that bovine lactoferrin, an inexpensive 
antimicrobial, antioxidant, anti-inflammatory dairy protein, substantially 
reduces sepsis, extending the benefits of probiotics.
LIFT brings together an international research team and parents committed 
to clinical trials to improve survival without disability in newborn babies. 
A cost-effectiveness analysis is also planned to capture completely the 
potential cost-effectiveness and societal benefits of lactoferrin in preventing 
major morbidity.
LIFT is an investigator-initiated trial, funded by NHMRC, which has 
established a new partnership with the internationally respected Vermont 
oxford Network, USA.
iNterNAtioNAL NeoNAtAL 
iMMUNotHerApy 
stUDy (iNis)
the ctc’s first trial in neonatal 
medicine was iNis, conceived in the 
late 1990s, started in 2001, and over 
6 years recruiting nearly 3500 infants 
from 9 countries. 
iNis was a trial of polyvalent igG 
immunoglobulin added to antibiotic 
therapy for newborn infants with 
serious infection. this was then a 
standard regimen for preventing later 
death and disability, a consequence of 
infection.
the trial showed that the additional 
immunoglobulin did not make a 
difference, evidence that is saving 
babies from an ineffective treatment 
and also saving its substantial cost.
lucille sebastian, manager of apts, with adrienne Kirby (foreground) and 
John simes, ctc director (background)
HIstorIcal
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WInner centre encompasses perinatal and neonatal trials at the ctc.
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WorKforce AND 
poVerty stUDies
the health economics group has in 
recent years carried out extensive 
research on the relationships 
between income, poverty, 
employment and various aspects 
of ill-health. these studies have 
been based on a model developed 
in collaboration with groups 
at the University of canberra, 
University of sydney and University 
of Queensland. recent studies 
have focused on specific chronic 
health conditions associated with 
premature retirement and loss 
of income, including arthritis,125 
psychiatric disorders,119,121 and 
cardiovascular disease.118,123 people 
with a chronic health condition 
are less likely to be employed 
than healthy people, and multiple 
conditions lead to greater costs from 
lower labour force participation, 
lower income, lower taxation 
revenue and higher government 
benefits.
in a related strand of this research, 
emily callander and the group have 
developed a new way of conceiving 
poverty —the freedom poverty 
Measure— a multidimensional 
poverty scale, which incorporates 
income, health and education status 
to measure disadvantage. ill-health 
is a major contributor to low living 
standards. the measure was used 
to explore the associations between 
chronic conditions and poverty, 
and it was found that arthritis, 
back problems and mental and 
behavioural disorders affected living 
standards most. of people with a 
chronic condition, 18% were poor 
by this definition, compared with 
only 4% of those without a chronic 
condition.20
Health economics
The economic impacts of ill-health 
can extend beyond the health system 
to affect family incomes, welfare 
payments, taxation revenue and 
special education.
potential to save costs 
beyond the health system
The health economics group is 
collaborating on the LIFT neonatal 
trial (p. 22). The economic evaluation 
includes developing a model of the 
relationship between improved 
cognitive outcomes in childhood and 
educational attainment.
ctc MAx colorectal  
cancer trial
Economic evaluations are an 
important part of assessments of 
new treatments and technologies; 
they must be shown to be value 
for money as well as effective. This 
is especially important for cancer 
treatments, where costs have been 
rising dramatically.
In Australia the cost per prescription 
has quadrupled in the past 
decade while expenditure by the 
pharmaceutical Benefits Scheme 
has increased even more. It is 
important that trials of new cancer 
drugs incorporate cost-effectiveness 
analyses to inform governments and 
other bodies making decisions about 
reimbursement.
In the AGITG MAX trial of combined 
treatment for advanced colorectal 
cancer (p. 9), data were collected 
during the trial for a study 
determining the cost effectiveness 
of adding a monoclonal antibody, 
bevacizumab, to chemotherapy. 
This was the first study to collect 
patient data as part of a prospectively 
designed economic study built into 
a phase III trial. Costs were analysed 
in relation to survival and quality of 
life. The regimen was found to be 
excessively expensive in proportion 
to its benefit. This lack of cost-
effectiveness could change if new 
biomarkers for treatment benefit 
allow targeted treatment.24
costs and quality-of-life 
impacts of prostate cancer 
screening in Australia
Screening the general population or 
people without symptoms for cancer 
adds to health costs but is generally 
not worthwhile and may even be 
harmful. But for people at high risk, 
the trade-off between the potential 
benefits, harms and financial costs 
may favour testing.
For example, a recently published 
study looked at prostate cancer 
screening in Australia.90 The current 
test used is a prostate-specific antigen 
(pSA) blood test, followed by more 
tests and possibly surgery if the test 
is positive. The costs of testing and 
treatment are high, especially when 
multiplied by the many middle-aged 
men who would be tested with 
universal screening. CTC statisticians 
and health economists developed a 
decision model to estimate the net 
benefit and cost of pSA screening 
versus no screening. They found that 
for the 1% of men who were at very 
high risk of prostate cancer, screening 
was cost-effective, but for others, 
the cost would be over $100 000 per 
quality-adjusted life year saved. What 
is needed now is a way of identifying 
each man’s level of risk.
continued…
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…Health economics (continued)
treatment of obesity
A randomised trial by the Boden 
Institute of obesity, Nutrition, 
Exercise & Eating Disorders (BIoNE) 
at the University of Sydney in 
collaboration with colleagues in the 
UK and Germany showed that referral 
to Weight Watchers produced greater 
weight loss, over 12 months, than 
attending a primary practitioner for a 
similar period.
BIoNE researchers and CTC health 
economists recently undertook 
cost-effectiveness analyses of the 
two approaches to weight loss. The 
Weight Watchers program was found 
to be more cost-effective on several 
health economic measures, such as 
dollars per kilogram lost, even though 
it involved more visits and more 
travel. outside the trial setting, the 
cost of such a commercial program 
would currently be borne by the 
individual, and in Australia, the cost 
of the primary practitioner would be 
covered by Medicare. The commercial 
program was cost-effective when 
modelled from the point of view of 
the health system.46
This analysis was extended in a 
model that extrapolated the trial 
data to project the outcomes for 
patients over a lifetime, finding that 
the commercial program continued 
to be more effective and less costly 
than primary care for improving the 
health of people who are overweight 
or obese.
AUstrALiAN NeW ZeALAND  
cLiNicAL triALs reGistry  
(ANZctr)
Medical evidence can be distorted if results of clinical trials are published 
selectively. Nearly three decades ago, John simes demonstrated this using the 
example of cancer trials to ‘illustrate an approach to reviewing the clinical trial 
literature, which is free from publication bias, and demonstrate the value and 
importance of an international registry of all clinical trials’.
in 1994 the ctc established a national registry of clinical trials in cancer, known as 
the Nctr, coordinated by Davina Ghersi, funded by the New south Wales cancer 
council, and affiliated with the Australian cochrane centre. the ctc’s registry 
group was then working with other groups, such as the register of european 
cancer trials, the register of UK cancer trials, and pDQ (physician Data Query) 
in the UsA, aspiring to make trial registration comprehensive and international. 
in the mid-1990s, information in the register was public, but distributed by 
newsletter. in 1998, the register passed 200 trial records, and in 1999 a website 
was set up.
in 2005, trial registration received a boost when the editors of many prestigious 
medical journals made prior registration mandatory for publication of results. the 
new Australian registry, with an Australia-wide advisory board, was established 
very quickly with funding from the NHMrc. it extended to all Australian research 
involving human participants and covered interventions such as pharmaceuticals, 
surgical procedures, preventive measures, lifestyle, devices, treatment strategies, 
rehabilitation strategies and complementary therapies. the Australian registry 
was one of the first to be recognised as a primary registry by the World Health 
organisation.
since 2005, the registry has continued to be developed by a team at the ctc, 
with ongoing funding from the NHMrc. By the end of 2013, 8755 trials were 
registered and the registry website had advanced in ease of use and linkage with 
other registries. in september, the ANZctr manager, Lisa Askie, was appointed 
as a member of the WHo international clinical trials registry platform advisory 
committee. the Australian registry is advancing and is well connected with 
international developments in trial registration, contributing to its original aims 
of universal registration of clinical trials.
HIstorIcal
Fergus tai, Kylie Hunter and Henry Ko, 
of the australian new Zealand clinical 
trials registry
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cocHrANe 
BreAst 
cANcer GroUp
John simes and Davina Ghersi 
established the cochrane Breast 
cancer Group, a registered review 
group of the cochrane collaboration, 
at the ctc in 1996. in 2001, the 
group received a major boost in 
funding from the Us Department 
of Defense, which enabled it to 
conduct a portfolio of systematic 
reviews addressing clinically 
relevant questions in advanced 
breast cancer. Nicholas Wilcken 
was the key person in seeing these 
reviews to completion and getting 
review findings into clinical practice 
guidelines internationally.
Nicholas Wilcken and Annabel 
Goodwin now lead the cochrane 
Breast cancer Group. the group has a 
moderate sized portfolio of clinically 
relevant reviews (70 reviews and 
protocols) and has strong consumer 
involvement at every level of the 
editorial process.
HIstorIcalcombining evidence for better clinical care
The best unbiased evidence on a 
particular aspect of clinical care 
is generally found in results of 
a systematic review of available 
research results. Systematic reviews 
with meta-analysis of trial results 
also estimate the effects of treatment 
more precisely than their constituent 
trials and may have enough data to 
show whether treatment effects vary 
in different subgroups. published 
systematic reviews assist clinicians in 
evidence-based decision making.
An improvement on basing a 
systematic review on trial results is to 
reanalyse the data in an individual-
participant-data meta-analysis. Such 
analyses have some of the advantages 
of a single large trial: better statistical 
precision in the results, the ability 
to show effects in subgroups 
of participants, and secondary 
hypothesis testing.
In prospective meta-analyses, trial 
investigators cooperate, often across 
national borders, to design their 
trials with future combined analysis 
in mind. Designs are harmonised 
in terms of entry criteria, sample 
size calculations and the choice and 
definition of trial endpoints agreed to 
in the meta-analysis protocol, before 
any results are known.
CTC authors conduct systematic 
reviews and individual-patient-data 
meta-analyses for peer-reviewed 
journals in various topic areas, such 
as neonatal disorders, cardiovascular 
disease9,171 cancer,65,84 and trial 
methodology.127
systematic reviews for the 
cochrane collaboration
The Cochrane Library is a database 
that contains high-quality, 
independent evidence from 
systematic reviews on a range of 
clinical questions to inform health-
care decision-making. Its work is done 
by specialist groups around the world 
that prepare, maintain and peer-
review these reviews, independent of 
commercial support. These reviews 
add value to trials already done by 
combining existing results and also 
take account of the quality of their 
methods and conduct, for example, 
by examining the risk of bias in each 
study.
The Cochrane Breast Cancer Group, 
which coordinates, edits and 
facilitates the publication of reviews 
on all aspects of breast cancer and 
recruits and trains new contributors, 
is based at the CTC. The group apply 
their content and methodological 
expertise to ensure that the protocol 
for conducting each review is rigorous 
and will lead to a comprehensive 
assessment of the current state of 
evidence.
In 2013, the group produced five 
new reviews—on chemotherapy, 
surgery, rehabilitation and detection 
of breast cancer—plus updates with 
new evidence of previously published 
reviews. They also facilitated the 
formulation of new protocols on 
aspects of surgery, radiotherapy, yoga 
and acupuncture.
davina ghersi and John simes
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a group at the ctc prepares assessments of new technologies for the Medical services 
advisory committee of the department of Health. left to right: samara lewis, Henry 
Ko, Briony Jack and elizabeth seil.
New medical technology: 
how do we know that it is 
effective and affordable?
In Australia, medical procedures 
are mainly funded by taxpayers. 
Therefore, the government requires 
evidence that new procedures and 
technologies are worth paying for 
and will benefit patients. Decisions 
are made by the Minister for Health 
on the advice of the Medical Services 
Advisory Committee.
The health technology assessment 
team at the CTC undertakes 
systematic reviews of new procedures 
being proposed for public funding. 
These are major reports that 
aggregate and evaluate evidence 
for safety, effectiveness and cost-
effectiveness.
over the past twelve months, the 
health technology assessment 
team has performed a review of 
the clinical effectiveness of cervical 
cancer screening technologies for the 
National Cervical Screening program 
Renewal and prepared assessments 
of the use of fiducial markers for 
radiotherapy in prostate cancer,  
cone beam computed tomography 
for dental imaging, and MRI 
screening for women at high risk  
of breast cancer.
Diagnostic testing as part of a clinical pathway  
that leads to the best outcome for the patient
Evaluation of diagnostic medical 
tests is different from trialling drugs 
and interventions in that a test does 
not affect health outcomes directly. 
Therefore, evaluation of tests has to 
include consideration of the doctors’ 
decisions and treatments that follow 
test results. The process as a whole 
must improve health, reduce costs 
or make health care delivery more 
efficient. Tests can only be justified if 
there is evidence of eventual benefit.
In the past decade, many advances 
have been made in test evaluation, 
much of it from the CTC. An example 
is development of a radiological 
sign distinguishing spinal stenosis 
from other causes of back pain. 
The concept, that nerve roots sink 
under gravity in the normal spine 
but do not move in the stenosed 
spine, was observed and shown to 
distinguish stenosis in 2010. The 
research group has now begun to 
examine the clinical pathway.6 They 
asked ‘Does the sign provide clinical 
information that can be used in 
treatment decisions and so improve 
health outcomes?’ in a study of 118 
patients attending a hospital clinic 
for back pain. The results suggested 
that the sign could help in identifying 
patients who might benefit from 
decompression surgery. Recent 
studies have been validating the test, 
through examining the biological 
mechanisms of the effect in animals4 
and in humans.5
The CTC’s Sally Lord is a member 
of the Test Evaluation Working 
Group of the European Federation 
of Clinical Chemistry and Laboratory 
Medicine, which has been developing 
a framework that considers the whole 
clinical pathway after laboratory 
testing for disease biomarkers.64 This 
is a concern of funding bodies, which 
want to see a benefit from expensive 
laboratory tests, and patients, who 
may be harmed by overdiagnosis  
and overtesting.
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Methodology
Biostatistical expertise 
applied to ctc trials and 
beyond
CTC biostatisticians are responsible 
for design, data analysis and 
validation of the analysis of trials 
initiated and conducted by the CTC 
and its collaborative groups. 
They also travel to various hospitals 
and universities in Sydney and 
elsewhere in Australia to take 
part in research studies in diverse 
clinical fields: Indigenous health, 
gynaecology, pregnancy and birth, 
cancers, radiology, psychiatry, heart 
disease, nutrition and health service 
delivery. over 50 such studies were 
published during 2013.
Urogynecology
Statisticians have collaborated with 
a group at the University of Western 
Sydney examining the demographic 
associations with and physical causes 
of perineal tearing during childbirth. 
They analysed data from over half a 
million births in New South Wales. 
Severe tearing often requires later 
surgical attention. It occurs during 
nearly 2% of Australian births, a rate 
that is increasing, especially in male 
births.113 
psychiatry
psychiatrists at Nepean Hospital 
in Sydney have been investigating 
obsessive-compulsive disorders 
in several studies.11–14 Statistical 
methods have been used to classify 
various manifestations of this 
disorder and to create models relating 
thoughts to symptoms.11 Factor 
analysis has been used to distinguish 
taboo thoughts from other kinds of 
obssessive-compulsive disorders and 
to identify other characteristics, such 
as substance abuse and hostility, that 
are associated with taboo thoughts.12
emergency services
The Head Injury Retrieval Trial 
is comparing care by a team 
that includes a doctor trained in 
emergency care with standard 
paramedic care for people rescued 
from accidents by helicopter. people 
with head injury often suffer from 
lack of oxygen and blood loss, and 
medical practitioners are able to 
provide more advanced procedures 
than paramedics. The CTC is working 
with Careflight on the study of cases 
from the Ambulance Service of New 
South Wales. The study design has to 
allow for the many individual factors 
that characterise serious accidents 
and injuries.48
CTC biostatisticans have collaborated 
with emergency staff at Royal prince 
Alfred Hospital, Sydney, on several 
studies of service delivery. They 
compared vital sign assessments at 
the scene of the injury and in the 
emergency department, with the aim 
of improving triage systems.37 Triage 
of trauma patients at the site of injury 
by ambulance services is essential to 
ensure that patients who need it go 
to trauma centres but less critically 
injured patients do not overload 
specialist hospital systems. They 
have also used statistical modelling 
to predict risk in injured patients35 
and have analysed the costs of injury, 
particularly in elderly patients.36
Val gebski, head of biostatistics
A Better rANDoMisAtioN MetHoD
one of the first new methods developed by the ctc biostatistics group, in the 
early 1990s, was dynamic balancing, an improvement on then current ways of 
randomising patients to trials. the method resolved the disadvantages of selection 
bias and imbalance in the treatment arms. the ctc author group said that:
‘imbalances in the numbers of patients receiving each treatment within individual 
subgroups can result in confounding bias. …Dynamic balancing is an intuitively 
simple, easily implemented scheme for use in centrally randomised trials. the 
method provides the trial coordinator with a greater degree of control over 
imbalances at all levels of stratification.’
— signorini et al. Statistics in Medicine, 1993
ctc biostatisticians elaine Beller and Val gebski take a break with professor paul 
glasziou at the meeting of the International society for clinical Biostatistics and the 
society for clinical trials, Brussels, in 1991.
Methodological research
Research on ways to improve the 
design and conduct of clinical trials 
has always been central to the CTC’s 
activities. This includes incorporating 
quality-of-life and cost-effectiveness 
studies into the design of trials92 and 
biostatistical studies that critically 
analyse current methods and propose 
new ones.
statistics-based guidance for 
systematic reviewers
When the benefit of a trial treatment 
becomes apparent early, and this 
is confirmed by statistical analysis, 
the trial may be stopped early. 
There are standard statistical 
procedures for this. But these 
calculations may overestimate the 
benefit of the treatment. When the 
results are combined with other 
trials in a systematic review, such 
overestimation might influence 
the combined evidence. Whether 
truncated trials should be included 
in systematic reviews and meta-
analyses has been widely debated. 
CTC biostatisticians Manjula Schou 
and Ian Marschner undertook a 
mathematical analysis of data from 
515 trials, considering possible 
estimation bias and also the effect 
of information weights used to 
aggregate the estimates in meta-
analyses.127 Finding that the 
combined evidence was not biased 
by data from truncated trials, they 
concluded that early stopping of 
clinical trials due to treatment benefit 
was not an important source of bias 
and recommended that systematic 
reviewers continue to include all trials 
in their calculations.
HIstorIcal
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MetHodologY
BiostAtistics 
for BreAst 
cANcer
professor John simes and professor 
Val Gebski have conducted and 
overseen statistical work for 
the Australia and New Zealand 
Breast cancer trials Group (p. 13) 
continuously for 25 years.
recently, researchers have used 
methods established by past ctc 
methodologists for assessing quality 
of life and treatment trade-offs to 
achieve authoritative approaches to 
balancing toxicity and survival.85
Multistate survival models in clinical trials
HIstorIcal
rachel o’connell, Val gebski, Jodie gonzalez-Jennings, elizabeth Barnes, anne-sophie Veillard, simone Marschner, 
from the biostatistics group
Survival of a trial patient without having the disease outcome is good for the 
patient, but causes challenges in time-to-event statistical analyses. A new 
method extrapolates information on events during a trial to predict possible 
later events.66 Biostatisticians used data from the LIpID study (p. 16) to 
demonstrate the method, which estimates the hazard ratio, overall survival 
and the benefit of treatment. ongoing long-term follow-up of LIpID patients 
for many years after the end of the trial will provide an opportunity for later 
validation of this method. 
david espinoza and andrew Martin
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tHe BcA Meets tHe NeeD 
for BiostAtisticiANs 
iN AUstrALiA
the founding of the BcA was an 
initiative coordinated by the ctc 
in the late 1990s. A shortage of 
biostatisticians in Australia was 
formally identified in 1999 in a 
review by the national public Health 
education and research program 
(pHerp). But such a specialised 
degree was beyond the wherewithal 
of any one university. in september 
1999, representatives of universities, 
government departments and 
industry met to plan a postgraduate 
coursework program in biostatistics 
delivered by distance education by a 
consortium of (then) 6 universities.
the Department of Health and Aged 
care provided seed funding for the 
BcA to launch the new courses and 
two subsequent rounds of funding, 
finishing in 2010. the BcA is now 
self-funding, via a capitation fee per 
unit of study enrolment. An office 
was established at the ctc, run by 
the executive officer, erica Jobling, 
and enrolments began in 2001. 
since then, around 300 students 
have graduated, 170 of these with a 
Master of Biostatistics.
since its inception, the BcA has 
developed into one of Australia’s 
most successful examples of a 
multi-institutional approach to 
addressing a critical skills shortage. 
in particular, it has delivered in high-
quality innovative programs beyond 
what would be feasible in any single 
institution. the key elements of 
the BcA’s success have been the 
critical mass from Australia’s most 
influential biostatistics groups 
together with a robust system of 
governance and ongoing review.
Masters degree in clinical trials research
As part of its education and training activities to improve the quality and scope 
of randomised trials in Australia, the CTC developed a postgraduate program 
in clinical trials research. Courses have been offered by Sydney Medical School 
since 2011. 
The program leads to formal qualifications from the University of Sydney in the 
design, conduct and interpretation of clinical trials.
The first students graduated in 2013, nine with a Master of Clinical Trials 
(Research) and two with a graduate diploma.
The program is coordinated by Adrienne Kirby, with directors Anthony Keech 
and Val Gebski, and is a major teaching commitment for many of the CTC’s 
academic staff.
Biostatistics collaboration of Australia
The BCA is currently a consortium of seven universities providing a well-defined 
path for the training of senior biostatisticians for clinical research. 
In 2013, there were 282 active students at the semester 2 census date. The BCA 
convened an external curriculum review to assess the relevance, completeness 
and standards of its current curriculum and recommend any changes. The 
reviewers interviewed former and current students, employers and potential 
employers, and representatives of industry and academia. 
CTC biostatisticians are active in teaching and coordinating BCA courses. In 
2013, Rachel o’Connell coordinated ‘Advanced clinical trials’. Elizabeth Barnes 
and Lucy Davies coordinated ‘principles of statistical inference’. 
Bca graduation at the university of sydney
HIstorIcal education
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collaBoratIons
collaborations
The CTC works with organisations around the world in collaborations that lead to better health outcomes in Australia and 
internationally. New collaborations are continually sought and then consolidated in research projects benefiting the health of 
Australians and others. 
group nature oF group ctc actIVItY
Australasian Gastro-Intestinal Trials Group 
(AGITG)
Collaborative group for gastrointestinal cancer trials: Australia, New Zealand Coordinating centre and 
collaborator
International collaborations: Cancer Clinical Trials Unit Scotland (CACTUS), 
Eastern Cooperative oncology Group (ECoG), European organisation for 
Research and Treatment of Cancer (EoRTC) , European Study Group for 
pancreatic Cancer (ESpAC) , Groupe Coopérateur Multidisciplinarie en 
oncologie (GERCoR), National Cancer Centre, Singapore, National Cancer 
Institute of Canada Clinical Trials Group (NCIC CTG) , National Surgical 
Adjuvant Breast and Bowel project (NSABp), Medical Research Council 
(MRC), oxford Clinical Trials office, oxford University (oCTo) , pan-European 
Trials in Alimentary Tract Cancer (pETACC)
Australasian Lung Cancer Trials Group (ALTG) Collaborative group for lung cancer trials: Australia, New Zealand Coordinating centre and 
collaborator
International collaborations: NVALT (Netherlands), NCIC CTG (Canada)
Australasian Society of Thrombosis and 
Haemostasis
professional group undertaking thrombosis trials: Australia, New Zealand Coordinating centre and 
collaborator
Australia New Zealand Gynaecological 
oncology Group (ANZGoG)
Collaborative group for gynaecological cancer trials: Australia, New Zealand Coordinating centre and 
collaborator
International collaborations: Dutch Gynaecologic oncology Group 
(DGoC), Group d’Investigateurs Nationaux pour l’Etude des Cancers 
ovariens (GINECo), Gynecological Cancer Intergroup (GCIG), International 
Gynaecological Cancer Intergroup (IGCI), Gynecologic oncology Group 
(GoG), Medical Research Council (MRC), Scottish Gynaecologic Cancer Trials 
Group (SGCTG)
Australian and New Zealand Urogenital and 
prostate Clinical Trials Group (ANZUp)
Collaborative group for cancer of the genitourinary system: Australia, 
New Zealand. International collaborations: Cancer Research UK (CRUK), 
European organisation for Research and Treatment of Cancer (EoRTC), 
Groupe Coopérateur Multidisciplinarie en oncologie (GERCoR),Institute of 
Cancer Research (ICR), National Cancer Research Institute (NCRI), Swedish & 
Norwegian Testicular Cancer project (SWENoTECA), and Wales Cancer Trials 
Unit (WCTU)
Coordinating centre and 
collaborator
Australian New Zealand Breast Cancer Trials 
Group (ANZ BCTG)
Collaborative group for breast cancer trials: Australia, New Zealand Statistical centre for group, 
including randomisation
International collaborations: International Breast Cancer Study Group 
(IBCSG), Breast International Group (BIG), International Breast Cancer 
Intervention Study (IBIS)
Australian New Zealand Clinical Trials Registry 
(ANZCTR)
National register of clinical trials: Australia, New Zealand and international Coordinating centre
Biostatistics Collaboration of Australia Universities undertaking postgraduate education in biostatistics: Australia Coordinating centre
Cholesterol Treatment Trialists’ Collaboration 
(CTTC)
Investigators of cholesterol treatment trials: Australia, New Zealand, United 
Kingdom, United States, Italy
Coordination of meta-
analyses in heart disease
Boden Institute of obesity, Nutrition, Exercise & 
Eating Disorders,
Research institution: Australia Collaborator
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Clinical Trial Development Unit (CTDU) partnership with the Centre for Biostatistics and Clinical Trials, peter 
MacCallum Cancer Institute: Australia
Trial operation and statistical 
support for cancer trials
Cochrane Collaboration Breast Cancer Group Collaborative group undertaking systematic reviews of trial evidence: 
international
Editoral base
Cochrane prospective Meta-Analysis Methods 
Group
Collaborative group undertaking systematic reviews of trial evidence: 
international
Coordinating centre
Cooperative Trials Group for Neuro-oncology 
(CoGNo)
Collaborative group for brain cancer trials: Australia Coordinating centre and 
collaborator
International collaborations: European organisation for Research and 
Treatment of Cancer (EoRTC)
Early prevention of obesity in Children (EpoCH) 
collaboration
prospective meta-analysis collaboration: international Data coordination centre
Fenofibrate and Event-Lowering in Diabetes 
(FIELD) Study Investigators
Collaborative group for FIELD diabetes trial genetic, molecular and follow-up 
substudies: Australia, New Zealand, Finland, Germany
Coordinating centre
Heart Foundation Nongovernment organisation: Australia Cardiovascular research
INSpIRE Meta-analysis: ASpIRE and WARFASA (Italy) Member
International Neonatal Immunotherapy Study 
(INIS) Study Group
Collaborative group for INIS trial: Australia, New Zealand, Europe, Argentina Regional coordinating centre
Long-term Intervention with pravastatin in 
Ischaemic Disease (LIpID) Study Group
Collaborative group for LIpID cholesterol-lowering trial genetic, molecular 
and follow-up substudies: Australia, New Zealand, Germany
Coordinating centre
Medical Services Advisory Committee (MSAC) 
and Department of Health and Ageing
Government: Australia Assessments of new 
technologies and other 
research services
Menzies Research Institute and Charles Darwin 
University
Research institution: Australia Collaborator 
Meta-analysis collaboration (AMICABLE) Meta-analysis collaboration: international Collaborator
Meta-Analysis of preterm patients on Inhaled 
Nitric oxide (MAppiNo ) collaboration
Meta-analysis collaboration: international Data coordination centre
National perinatal Epidemiology Unit (NpEU), 
University of oxford
Research institution: UK Collaborator on the INIS 
neonatal trial
Neonatal oxygenation prospective Meta-
analysis (NeoproM) collaboration
prospective meta-analysis collaboration; international Coordinating centre
NSW Cancer Council Cancer Epidemiology Research Unit Collaborator
perinatal Antiplatelet Review of International 
Studies (pARIS) collaboration
Meta-analysis collaboration: international Co-coordinating centre
prenatal repeat corticosteroid international 
individual-patient-data study group: assessing 
the effects using the best level of evidence 
(pRECISE) collaboration
Meta-analysis collaboration: international Collaborator
prevention of Ventilator Induced Lung Injury 
collaborative study group (preVILIG) 
Meta-analysis collaboration: international Data coordination centre
primary Care Cancer Trials Group (pC4) Collaborative group: Australia Collaborator
primary Coronary Angioplasty versus 
Thrombolysis (pCAT)
Meta-analysis collaboration: international Co-coordinating centre
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collaBoratIons
group nature oF group ctc actIVItY
prospective pravastatin pooling (ppp) project Collaborative group: international Coordinating centre
RNA-based Analysis for prediction of Islet 
Death (RApID)
Collaborative group: Australia Collaborator
REMoVAL trial group Collaborative group: international Coordinating centre and 
collaborator
Royal Australasian College of Surgeons (RACS) professional society undertaking trials of surgery: Australia and New Zealand Coordinating the SNAC 
trials in breast cancer with 
the RACS
Sydney Catalyst Consortium for translational research in cancer Collaborator
Trans-Tasman Radiation oncology Group 
(TRoG)
Collaborative group: Australia and New Zealand Collaborator
T4DM trial group Collaborative group: Australia Coordinating centre and 
collaborator
Star Child Health Meta-analysis collaboration: international Member
University of Melbourne Department of 
Medicine
Research institution: Australia Collaborator on diabetes 
studies
WINNER Centre for Newborn Research Collaboration for international neonatal trials: Australia Collaborator
funding
Funder
National Health and Medical Research Council 7,105,094
Australian Research Council 220,202
Cancer Australia 3,526,895
Cancer Council 316,101
Cancer Institute New South Wales 2,084,412
Collaborative investigator groups 34,652
other research grants 2,046,277
overseas research grants 1,605,594
other Australian public funding 1,253,451
Research infrastructure grants 2,260,027
pharmaceutical industry, primarily for trials 2,798,621
Consulting 422,622
Student Fees 141,832
other 966,101
24,781,881
● National Health and Medical Research Council
● Cancer Australia, Cancer Institute NSW  
   and Cancer Council
● other public funding
● overseas research grants
● pharmaceutical industry
● other
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current ctc trials
trIal partIcIpants target accrual
neonatal dIsorders
trials in start-up
LIFT: Lactoferrin infant feeding trial 
CTC-led study
Infants born weighing under 1500 g 1100 –
current trials
ApTS: Australian placental transfusion study 
CTC-led study
Neonates born before 30 weeks’ gestation  1600 657
trials in follow-up
BooST II: Benefits of oxygen saturation targeting 
CTC-led study
Neonates born before 28 weeks’ gestation  1200 1135
cardIoVascular and dIaBetes
trials in start-up
FAME1-EYE: Fenofibrate and microvascular events in type 
1 diabetes 
CTC and University of Melbourne
Adults with type 1 diabetes and some 
thickening of the macula of the eye
450 –
current trials
REMoVAL: Effects of metformin added to insulin on 
atheroma progression  
University of Glasgow and NHS-led, and CTC study
Adults with type 1 diabetes at risk of 
cardiovascular disease
90 (ANZ):  
500 (international)
52 (ANZ):  
441 (international)
T4DM: efficacy of adding testosterone to a lifestyle program 
to prevent progression to type 2 diabetes 
University of Adelaide and CTC study
Men with prediabetes and low testosterone 1500 109
trials in follow-up
FIELD: Fenofibrate intervention and event lowering in 
diabetes 
CTC-led study
patients with type 2 diabetes 8000 9795
LIpID: Long-term intervention with pravastatin in ischaemic 
disease 
CTC-led study
patients with a history of coronary heart 
disease
9000 9014
oncologY prognosIs studY
current trials
iTool: Evaluating a web-based tool for estimating and 
explaining prognosis 
CTC study
patients with incurable cancer who attend 
clinics of participating oncologists and who 
want information about life expectancy
70 patients;  
70 oncologists
40 patients;  
6 oncologists
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ctc current trIals
trIal partIcIpants target accrual
Breast cancer (collaBoratIng WItH racs)
current trials
SNAC 2: Sentinel node biopsy versus axillary clearance 
RACS and CTC study
Women with operable breast cancer, stratified 
by factors including age and tumour size
1012 298
trials in follow-up
SNAC 1: Sentinel node biopsy versus axillary clearance  
RACS and CTC study
Women with a single operable breast tumour 
<3 cm, stratified by factors including age and 
tumour size
1000 1088
gastroIntestInal cancer (collaBoratIng WItH agItg)
trials in start-up
ASCoLT: Aspirin for Dukes C and high-risk Dukes B colorectal 
cancers 
National Cancer Institute (Singapore)-led, AGITG and CTC study
patients with colorectal cancer who have 
completed surgery and other treatment
200 (Australia);  
2660 international
–
current trials
A La CART: Australian phase III randomised trial of 
laparoscopy-assisted resection compared with open 
resection 
AGITG and CTC study
patients with primary rectal cancer 470 315
Co.23: BBI608 and supportive care compared with placebo 
and supportive care for colorectal carcinoma  
NCIC-CTG-led AGITG and CTC study
patients with advanced colorectal carcinoma 275 (ANZ);  
650 (international)
42 (ANZ)
DoCToR: phase 2 trial of preoperative cisplatin, 
5-fluorouracil and docetaxel with or without radiotherapy for 
oesophageal cancer 
AGITG and CTC
patients with resectable adenocarcinoma 
of the oesophagus not responsive to 
chemotherapy
150 72
GAp: phase 2 study of gemcitabine and NAB-paclitaxel 
AGITG and CTC
patients with resectable pancreas cancer 50 28
ICECREAM: Irinotecan cetuximab evaluation and cetuximab 
response evaluation among mutants 
AGITG- and CTC-led international study
patients with Kras-WT metastatic colorectal 
carcinoma or a G13D mutation
100 40
IMpACT: phase 2 trial using genomic sequencing and protein 
expression to direct first-line treatment  
Garvan, AGITG and CTC
patients with metastatic pancreatic cancer 20 1
INTEGRATE: phase 2 trial comparing regorafenib and 
placebo 
AGITG and CTC-led international
patients with advanced oesophagogastric 
cancer
150 135
SCoT: Short-course oncology therapy, a study of adjuvant 
chemotherapy in colorectal cancer 
MRC-led, AGITG and CTC
patients with fully resected stage III colorectal 
cancer
225 (ANZ):  
9500 (international)
213 (ANZ);  
6144 (international)
TopGEAR: Randomised phase II–III trial of preoperative 
chemoradiotherapy versus preoperative chemotherapy for 
gastric cancer 
AGITG- and CTC-led international study
patients with resectable gastric cancer 
suitable for these treatments
120 (stage 1);  
632 (stage 2)
98 (stage 1)
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trIal partIcIpants target accrual
trials in follow-up
Adjuvant GIST: Adjuvant imatinib mesylate versus no further 
therapy after complete surgery (AG0403, EoRTC 62024) 
EORTC-led, AGITG and CTC
patients with resected gastrointestinal 
stromal tumours (GIST) expressing KIT 
receptor
80 (ANZ) 81 (ANZ);  
908 (international)
Advanced GIST: Relation between dose and clinical activity of 
imatinib mesylate (AG0102, EoRTC 62005) 
EORTC-led, AGITG and CTC
patients with unresectable or metastatic 
malignant gastrointestinal stromal tumours 
(GIST) expressing KIT receptor
80 (ANZ):  
600 (international)
116 (ANZ);  
946 (international)
ATTACHE: Timing of surgery and adjuvant chemotherapy for 
hepatic colorectal metastases 
AGITG and CTC study
patients with confirmed resectable liver 
metastases and no other disease
200 9
EoRTC liver metastases: oxaliplatin, 5-fluorouracil and 
leucovorin versus surgery for resectable colorectal cancer 
liver metastases (EoRTC 40983) 
EORTC-led, AGITG and CTC
patients with colorectal cancer with resectable 
liver metastases
330 (international) 35 (ANZ);  
364 (international)
LAp07: Randomised multicentre phase III study of 
gemcitabine with or without chemoradiotherapy and with or 
without erlotinib  
GERCOR-led, AGITG and CTC
patients with locally advanced 
adenocarcinoma of the pancreas
60 (ANZ);  
900 (international)
32 (ANZ);  
442 (international)
pAN1: phase II study evaluating potential predictive 
biomarkers in treatment of locally advanced and metastatic 
pancreatic cancer  
AGITG and CTC
patients with confirmed metastatic pancreatic 
adenocarcinoma
80 13
pETACC 6: Addition of capecitabine to preoperative 
oxaliplatin chemoradiotherapy and postoperative oxaliplatin 
chemotherapy for rectal cancer (AG0707R) 
EORTC (PETACC)-led, AGITG and CTC
patients with locally advanced rectal cancer 135 (ANZ);  
1090 (international)
127 (ANZ);  
1094 (international)
Quasar 2: phase III study of capecitabine and bevacizumab as 
adjuvant treatment of colorectal cancer (AG0107CR) 
OCTO-led, AGITG and CTC
patients with colon cancer treated by surgery 120 (ANZ);  
1892 (international)
219 (ANZ);  
1952 (international)
REGISTER: Multicentre phase II study of risk evaluation in 
GIST with selective therapy escalation for response 
AGITG- and CTC-led international study
patients with gastrointestinal stromal tumour 
not suitable for curative surgery
80 47
TACTIC: phase 2 trial of panitumumab, cisplatin and 
gemcitabine  
AGITG and CTC
patients with biliary tract cancer 45 48
gYnaecologIcal cancer (collaBoratIng WItH anZgog)
current trials
ICoN 8: Dose-fractionated chemotherapy compared with 
3-weekly chemotherapy for ovarian cancer 
MRC-led ANZGOG and CTC study
Women with ovarian, fallopian tube or 
primary peritoneal cancer.
145 (ANZ);  
1485 (international)
3 (ANZ);  
794 (international)
ANZGoG-1103: phase I–II BNC105p combination study 
ANZGOG- and CTC-led international study
Women with partly platinum-sensitive 
ovarian cancer in first or second relapse
phase 1: up to 24 
(international)
15
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trIal partIcIpants target accrual
outback: phase III trial of addition of adjuvant chemotherapy 
to standard chemoradiation as primary treatment for cervical 
cancer (ANZGoG-0902) 
ANZGOG- and CTC-led international study
Women with locally advanced cervical cancer 780 (international) 68 (ANZ);  
195 (international)
pARAGoN: phase II study of anastrozole in gynaecological 
cancers (ANZGoG-0903) 
ANZGOG- and CTC-led international study
Women with potentially hormone-responsive 
gynaecological cancers
350 (international) 175 (ANZ);  
58 (international)
poRTEC 3: Chemo radiation and adjuvant chemotherapy 
compared with pelvic radiation alone in high-risk 
endometrial carcinoma 
DGOG-led, ANZGOG and CTC study
Women with advanced endometrial 
carcinoma
120(ANZ);  
670 (international)
121 (ANZ);  
671 (international)
REZoLVE: phase II study to evaluate the safety and potential 
palliative benefit of intraperitoneal bevacizumab 
ANZGOG and CTC study
Women with symptomatic ascites due to 
advanced chemotherapy-resistant ovarian 
cancer
16` 1
Symptom benefit: Does palliative chemotherapy improve 
symptoms in women with recurrent ovarian cancer? 
(ANZGoG-0701) 
ANZGOG- and CTC-led international study
Women with platinum-resistant or refractory 
ovarian cancer
200 (ANZ);  
800 (international)
126 (ANZ);  
439 (international)
trials in follow-up
CALYpSo 
GINECO-led, ANZGOG and CTC
Women with platinum sensitive relapsed 
ovarian cancer
974 (international) 71 (ANZ) 
976 (international)
GoG182 
GOG-led, ANZGOG and CTC
Women with advanced stage (FIGo III-IV) 
epithelial ovarian or primary peritoneal 
carcinoma.
4200 (international) 184 (ANZ),  
4312 (international)
GoG199 
GOG-led, ANZGOG and CTC
Women at high risk of ovarian cancer 800 (international) 83 (ANZ),  
800 (international)
ICoN 6: Safety and efficacy of cediranib in combination with 
standard chemotherapy 
MRC-led, ANZGOG and CTC
Women with platinum-sensitive relapsed 
ovarian cancer
400 (international) 17 (ANZ);  
486 (international)
ICoN 7: Randomised trial of adding bevacizumab to standard 
chemotherapy 
MRC-led, ANZGOG and CTC
Women with epithelial ovarian cancer who 
had not received systemic antitumour therapy
1444 (international) 76 (ANZ);  
1450 (international) 
oVAR 16: pazopanib versus placebo for ovarian cancer 
AGO-led, ANZGOG and CTC
Women without disease progression after 
chemotherapy for epithelial ovarian, fallopian 
tube, or primary peritoneal cancer
900 (international) 65 (ANZ);  
940 (international)
SCoTRoC 4: Multicentre trial of carboplatin flat dosing vs 
intrapatient dose escalation in first-line chemotherapy  
SGCTG-led, ANZGOG and CTC
Women with ovarian, fallopian tube or 
peritoneal carcinoma who are unsuitable for 
platinum–taxane therapy
1300 (international) 64 (ANZ);  
937 (international)
EoRTC55041 Tarceva 
EORTC-led, ANZGOG and CTC
Women without disease progression after 
chemotherapy for epithelial ovarian, fallopian 
tube, or primary peritoneal cancer
830 (international) 41 (ANZ),  
830 (international)
TRIpoD (ANZGoG-0601) 
ANZGOG and CTC
Women with optimally debulked stage III 
cancer of the ovary, peritoneum and fallopian 
tube.
35–100 39
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genItourInarY cancer (collaBoratIng WItH anZup)
trials in start-up
BCG+MMC: phase III trial of adding mitomycin C to BCG as 
adjuvant intravesical therapy for bladder cancer 
ANZUP and CTC study
patients with high-risk, non-muscle-invasive 
bladder cancer
500 –
p3BEp: phase III trial of accelerated versus standard BEp 
(ANZUp 1302) 
ANZUP, ANZGOG and CTC study
patients with intermediate and poor-risk 
metastatic germ-cell tumours
phase 1: 90 (ANZ); 
150 (international)
phase 2: 350
–
trials in follow-up
Chemo & cognition: Cognitive function and treatment for 
testicular cancer (ANZGCTG 0106) 
ANZUP and CTC
patients being treated and followed up for 
testicular cancer
154 151
Eversun: phase II trial of everolimus alternating with 
sunitinib for renal cell carcinoma (ANZUp 0901) 
ANZUP and CTC
patients starting first-line systemic therapy for 
advanced renal cell carcinoma
55 55
SoRCE: Adjuvant sorafenib for renal cell carcinoma (RE 05) 
MRC-led, ANZUP and CTC
patients with resected renal cell carcinoma at 
intermediate or high risk of relapse
 250 (ANZ);  
1656 (international)
1711
lung cancer (collaBoratIng WItH altg)
current trials
NITRo: phase III multicentre trial of adding nitroglycerine 
to first-line chemotherapy for advanced non-small-cell lung 
cancer (ALTG 06/003) 
ALTG and CTC
patients with advanced non-small-cell lung 
cancer
 500 350
trials in follow-up
BR.26: phase III trial of pF-804 in patients with incurable, 
non-small-cell lung cancer (ALTG 09/002) 
NCIC-led, ALTG and CTC
patients with stage IIIB or IV non-small-cell 
lung cancer
180 88
B2p2M2: phase II trial of BNC105p as second-line 
chemotherapy for pleural mesothelioma (ALTG 09/004)
ALTG and CTC
patients with pleural mesothelioma which 
has progressed after pemetrexed and 
platinum chemotherapy
 60 30
pACT in NSCLC: preferences for adjuvant chemotherapy in 
non-small-cell lung cancer 
ALTG and CTC observational study
patients, surgeons and oncologists 200 122
BraIn cancer (collaBoratIng WItH cogno)
current trials
CATNoN: phase III trial of concurrent and adjuvant 
temozolomide chemotherapy for anaplastic glioma (EoRTC 
26053-22054) 
EORTC-led, COGNO and CTC
patients with non-1p/19q- deleted anaplastic 
glioma
100 (ANZ);  
748 (international)
54 (ANZ);  
542 (international)
trials in follow-up
CABARET: phase II study of carboplatin and bevacizumab in 
recurrent glioblastoma multiforme 
COGNO and CTC
patients aged 18 years and over with 
recurrent grade IV glioma after radiotherapy 
and temozolomide chemotherapy
122 (part 1);  
60 (part 2)
122 (part 1);  
48 (part 2)
SEED: Self-reported evaluation of the adverse effects of 
dexamethasone 
COGNO and CTC
patients with brain tumours or brain 
metastases or advanced cancer using steroids
50 patients,  
50 caregivers
66 patients,  
66 caregivers
ctc current trIals
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staff
ctc executive
R John Simes, BSc(Med)(hons), MB BS(hons), 
MD, SM, FRACp, director and senior 
principal research fellow
Anthony C Keech, MB BS, MSc, FRACp, 
FCSANZ, deputy director and principal 
research fellow
Wendy Hague, MB BS, MBA, phD, director, 
clinical trials program, and senior research 
fellow
Kim Russell-Cooper, BA(hons), MBA, general 
manager
executive support
Thalia Hambides, executive assistant to the 
director
Katie Doyle, executive assistant to the deputy 
director
oncology trials
Martin R Stockler, MB BS(hons), MSc, FRACp, 
cancer trials co-director and professor
oncology trials managers
Burcu Vachan, BSocSc(hons), MpH, DipMan, 
oncology program manager
Sarah Chinchen, BSc(hons), MpH, operations 
associate program manager and mentor
Xanthi Coskinas, BHlthSc, GradDipHIM, 
MSc(ClinEpi), development associate 
oncology program manager, ANZUp
Kim Gillies BA(hons), MHlthSc, operations 
oncology associate program manager, 
ANZGoG
Ann Livingstone, RN, MHlthServMgt, 
development associate oncology program 
manager, CoGNo and ALTG
Julie Martyn, BSc, GradDip HortSc, phD, 
development associate oncology program 
manager, ANZGoG
Danielle Miller, BSc(hons), MpH, associate 
oncology program manager, pC4, Sydney 
Catalyst research manager
Kate Sawkins, BAppSc(phty)(hons), 
operations associate oncology program 
manager, CoGNo and ALTG
Lucille Sebastian, BSc(hons), phD, manager, 
special projects
Eric Tsobanis, BScN(hons), MBA, operations 
associate oncology program manager, 
AGITG and ALTG
Kate Wilson, BA, MpH, development associate 
oncology program manager, AGITG
Nicole Wong, RN, BN, BSc(hons), operations 
associate oncology program manager, 
AGITG
oncology trials staff
Christine Aiken, BSocSc, MHlthSc
Adeeba Aziz, BBiomedSc
Lisa Bailey, BAppSc
Karen Bracken, BEc, MpH
Lesley Brassel, BMgmt, DipEvents
Hannah Cahill, BAppSc, BA
Lily Cakir, BA, MTeach
David Cannan, BSc(hons)
Kerrie Carlton, BAppSc, MSc, GradDipBioethics
John Flynn
Alyson France, BSc/BTeach, GradDipAppSc
Lara Hall
Merryn Hall, BSc
Ilka Kolodziej, BAppSc(hons), MpH
Joseph Levitt, RN
oliver Martyn, BExphys
Angus McDonald, BEc(SocSc)
Karen Miranda, BBiomedSc
Jenna Mitchell, BHSc(hons), BBiomedSc
Nick Muljadi, BSc(hons)
Kate Roff, BSc(hons)
Beau Salwin, BSc, GradDipAppSc, MMedSc
Shona Silvester, BSc, MMedSc
Helen Taylor, BSc, phD
Jennifer Thompson, Cert IV BusAdmin
Bernadette Tomes, BClinSc
Diana Winter, BMedSc
oncology research fellows
Rasha Cosman, BSc(Med), MBBS, FRACp, 
clinical research fellow, ALTG and CoGNo
Danielle Ferraro, MB BS (hons), FRACp, clinical 
research fellow, ALTG and AGITG
Belinda Kiely, BSc(Med), MB BS, phD, FRACp, 
senior clinical research fellow
Chee K Lee, MB BS(hons), MB BS(hons), 
MMedSc, MBiostat, phD, FRACp, clinical 
lead
Anne Long, FRACp, BM BS, BSc(hons), clinical 
research fellow, ANZGoG and ANZUp trials
Katrin M Sjoquist, BSc(Med), MB BS, 
MClinT(R), FRACp, clinical lead
Dirkje W Sommejier, MD, phD, clinical 
research fellow, AGITG and ANZGoG
Sonia Yip, BSc(hons), phD, oncology senior 
translational research fellow and manager
cooperative trials Group  
for Neuro-oncology
Jenny Chow, AssocDip, executive officer
Yi Feng, administrative assistant, 
BE(aeronautical)(hons)
Hannah o’Riley, BSc(hons), administrative 
assistant
Karen Miranda, trial coordinator and monitor, oncology
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Neonatal trials
William o Tarnow-Mordi, MRCp(UK), 
FRCpCH, coordinator of neonatal trials 
and head, WINNER Centre for Newborn 
Research
iNis and Apts trials
Lucille Sebastian, BSc(hons), phD, project 
manager
Rebecca Brown, BSc(hins), clinical trials 
assistant
Caitlin van Holst pellekaan, BMedSc(hons), 
data manager
Boost ii trial
Alpana Ghadge, BSc, MSc, phD, GradCert 
TradeMarksLawpract, project manager
Lift trial
Alpana Ghadge, BSc, MSc, phD, GradCert 
TradeMarksLawpract, project manager
Rebecca Brown, BSc(hons), clinical trial 
assistant
cardiovascular trials
fieLD follow-up 
Li ping Li, BMed, GradCertDM, project 
manager
San Yip Chan, administrative assistant
Sandra Healey, BA(hons), GradDipFA, RN, 
substudy coordinator
Aspire
Rebecca Mister, BSc, MSc, project manager
Rebecca Brown, BSc(hons), clinical trial 
assistant
Caitlin van Holst pellekaan, BMedSc(hons), 
data manager–study monitor
LipiD follow-up
Helen pater, BAppSc, project manager
Diabetes trials
reMoVAL
Helen pater, BAppSc, project manager
t4DM
Karen Bracken, BEc, MpH, project manager
Caitlin van Holst pellekaan, BMedSc(hons), 
data manager–study monitor
Quality assurance
phillipa Smith, Bpharm(hons), MSc, head of 
quality assurance
Karen Wilkinson, DipTeach, BA, postgradDip 
psychol, MRQA, clinical trials auditor
clinical data management
Mark Maclean, BA, DCR(T), CM, head
Salma Fahridin, BAppSc(HIM), MHlthSc, 
clinical data coordinator
Liam Murphy, BSc, clinical data coordinator
Michelle M parry, BSc, phD, clinical data 
project manager
Lindsay Stevens, BSc, clinical data coordinator
site management
Rebecca Mister, BSc, MSc, head
Diabetes molecular medicine  
and telehealth
Alicia J Jenkins, MB BS, MD, FRACp, FRCp, 
professor of diabetes and vascular medicine
Sven-Erik Bursell, phD, professor of telehealth
Anandwardhan A Hardikar, BSc,MSc, phD, 
associate professor, Australian Future Fellow 
(ARC)
Andrzej S Januszewski, MD, phD, senior 
research fellow
Mugdha Joglekar, BSc, MSC, phD, Juvenile 
Diabetes Research Foundation research 
fellow
Daniel Calandro, BSc, research assistant
Veronica Dy, phD, clinical trial assistant
Thomas McCorquodale, BSc, clinical trial 
assistant
Sarang Satoor, BSc, MSc, research fellow
systematic reviews and health 
technology assessment
Lisa M Askie, BN, MpH, phD, director, and 
principal research fellow
Jenny Chow, AssocDip, executive officer
Henry CH Ko, BEng(Med)(hons), phD, 
research fellow
Sally J Lord, MB BS, Dippaed, MS, FRACGp, 
epidemiologist and research fellow
Health technology assessment 
Briony Jack, phD, project manager
Samara Lewis, BA/BSc(hons), phD, project 
manager
Elizabeth Seil, BA(hons), MSc(HTA), project 
officer
Anna Stoklosa, BA, MA, phD, research fellow
Sally Wortley, BHlthSc(hons), MpH, Grad Cert 
Hlth Econ, project officer
cochrane breast cancer review group
Melina Willson, BSc (hons)/BA, phD, 
managing editor
Fergus Tai, BAppSc, DipIT, MpH, trials search 
coordinator
Australian New Zealand  
clinical trials registry
Kylie E Hunter, BA, BA(hons), project officer
William YT ooi, MHlthSc, BAppSc, project 
officer 
In april, Jenny chow received a 
Faculty of Medicine award for 
exceptional performance
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phD, professor
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research fellow
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fellow
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professor
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DIC, CStat RSS, senior lecturer
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research fellow
research fellow
Elizabeth H Barnes, BAppSc, MStat
Biostatisticians
Luke Buizen, BSc
Lucy Davies, BSc, MSc
Mark W Donoghoe, BSc(hons)
David Espinoza, BSc(hons)
Emma Gibbs, BSc, MSc
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(BcA)
Erica Jobling, executive officer
Kew Flood, administrative officer
information systems
infrastructure
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Asanka perera, BSc, computer systems officer
Ha Le, BCST, desktop support officer
Ryan Sausa, BE, computer systems officer
Thuyen Vu, BSc, computer systems officer
Database administration
Anh Tai Nguyen, BMath, database 
administrator
software development
Colin Sutton, BSc, MSc, IT systems 
development manager
Seshu Atluri, BE, software engineer
Business administration
Kim Russell-Cooper, BA(hons), MBA, general 
manager
Lily Cakir, receptionist
Mira Mikulic, receptionist
Lia Sherwood, BBiomedSc, MSc, grants and 
contracts coordinator
finance
paul Smyth, BCom, CpA, finance manager
Agnes Ho, MpracAcc, CpA, finance officer
Maki Joseph, DipEd, finance officer
Carlos Sterling, BEng, MBA, finance officer
Human resources
Cynthia Carr, BEd(HRD), human resources and 
administration manager
Suzanne Everett, BSW, human resources and 
administration coordinator
publications
Rhana pike, BA, MA, GradCert, ELS, CMpp, 
senior publications officer
research students
Daniel Calandro, BSc
Venu Chalasani, MB BS, FRACp
Ryan Farr, BSc, Mphil 
Jordan Fulcher, BSc(Med), MB BS
Deme Karikios, BSc, MB BS, FRACp
Kushwin Rajamani, MB BCh
Ru-Dee Ting, MB BS, FRACp
Boris Waldman, BSc
Wilson Wong, BSc(hons) 
Academic staff
Lisa M Askie, BN, MpH, phD, associate 
professor and principal research fellow
Elizabeth H Barnes, BAppSc, MStat, research 
fellow
Karen Byth, BSc(hons), MSc, phD, DIC, CStat 
RSS, senior lecturer
Emily J Callander, BA, phD, research fellow
Hannah Carter (Verry), BEc, research associate
Michelle Cunich, BEc, phD, economist
Val J Gebski, BA, MStat, professor and 
principal research fellow
Wendy Hague, MB BS, MBA, phD, senior 
research fellow
Anandwardhan A Hardikar, BSc, MSc, phD, 
associate professor and Australian Future 
Fellow (ARC)
Andrzej S Januszewski, MD, phD, senior 
research fellow
Alicia J Jenkins, MB BS, MD, MRCp, FRACp, 
FRCp, professor
Anthony C Keech, MB BS, MSc, FRACp, 
FCSANZ, principal research fellow and 
professor
Adrienne C Kirby, BSc(hons), MSc, senior 
lecturer
Henry Ko, BEng(Med)(hons), phD, research 
fellow
Chee K Lee, MB BS(hons), MMedSc, MBiostat, 
phD, FRACp, senior research fellow
Sally (Sarah) J Lord, MB BS, Dippaed, MS, 
FRACGp, senior research fellow
Sharyn Lymer, BA, Bpthy, MBiostat, phD, 
research fellow
Ian C Marschner, BSc(hons), phD, professor
Andrew J Martin, BA, MA, GradDip, phD, 
AStat, senior lecturer
Rachel L o’Connell, BMath, MMedStat, phD, 
senior research fellow
Deborah J Schofield, BSppath, GradDipComp, 
phD, professor
Mark Maclean, head,  
clinical data management
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professor Sanjeev Galande, Diabetes, 
Molecular Medicine and Telehealth
professor Alexander Gallus, ASpIRE trial 
management committee
Dr Davina Ghersi, Australian New Zealand 
Clinical Trial Registry advisory committee 
and CTC adjunct professor
professor p Grantley Gill, pI, SNAC trials
Dr David Goldstein, pI, LAp07 trial, co-pI, 
ATTACHE trial, AGITG board
Dr Andrew M Haydon, pI, SCoT trial (AGITG)
Dr Sandra Hayes, ECHo study
professor Dickon Hayne, pC4 trial, ANZUp
Dr Elizabeth Hovey, CoGNo executive
Dr H Malcolm Hudson, Biostatistics
Dr Monika Janda, CoGNo scientific advisory 
committee
Dr Michael Jefford, SCoT trial (AGITG)
Dr Lindy Jeffree, CoGNo scientific advisory 
committee
Dr Terrance Johns, CoGNo management 
committee
Dr David J Joseph, CoGNo scientific advisory 
committee
Dr Andrew Kneebone, AGITG
Dr Eng-Siew Koh, CoGNo management 
committee
Dr Dusan Kotasek, Adjuvant GIST study
Dr Danette Langbecker, CoGNo scientific 
advisory committee
Ms Robyn Leonard, CoGNo management 
committee
Dr Trevor Leong, pI, Top GEAR, Gastric trial 
(AGITG)
Dr Helen Liley, pAEAN study
Dr Kerrie McDonald, CoGNo scientific 
advisory committee
Dr Sue-Anne McLachlan, pACT in SCLC 
(ALTG)
Associate professor peter Meikle, LIpID and 
FIELD studies
Dr Michael Michael, pI, TopGEAR trial 
(AGITG)
Dr Linda Mileshkin, ANZGoG executive, 
pI,poRTEC-3 and oUTBACK trials
professor Michael J Millward, pI, BR26 trial 
(ALTG)
Associate professor paul Mitchell, ALTG
Dr paul Nguyen, ANZUp
professor Anna Nowak, pI, CATNoN trial 
(CoGNo)
Dr Robert padbury, AGITG
Dr Nicholas J petrelli, AGITG
Associate professor Timothy J price, pI, 
pETACC6 trial (AGITG)
Dr Kushwin Rajamani, FIELD study
Dr David T Ransom, pI, SCoT and ARCTIC 
trials (AGITG)
Dr Danny Rischin, ANZGoG executive
Dr Aflah Roohullah, AGITG
Dr Mark Rosenthal, CoGNo chair
Dr Gail Ryan, CoGNo scientific advisory 
committee
Associate professor Eva Segelov, pI, 
ICECREAM, QUASAR2 and SCoT trials 
(AGITG)
Dr Shomik Sengupta, ANZUp
Dr Catherine Shannon, oVAR 2.21 (ANZGoG)
Dr Jennifer A Shannon, pI, TACTIC trial 
(AGITG)
Dr Bernard M Smithers, Gastric trial (AGITG)
Dr Benjamin Solomon, pI, BR24 trial (ALTG)
Dr Allan Spigelman, Sydney Catalyst
Dr Nigel A Spry, pI, LAp07 trial (AGITG)
Dr Andrew R Stevenson, pI, A La CART 
(AGITG)
Associate professor David Sullivan, LIpID and 
FIELD trial management committees
Dr Christopher Sweeney, ANZUp
Associate professor Niall Tebbutt, pI, ATTAX, 
ATTAX2, ATTAX3 and MAX trials (AGITG)
Associate professor Damien Thomson, co-pI, 
Aprepitant trial (ANZUp) and ANZUp germ-
cell subcommittee
Dr Andrew Tonkin, BiomarCare, LIpID study 
chair
Dr paul Vasey, pI, SCoTRoC4 trial (ANZGoG)
Dr Michelle Vaughan, ANZGoG executive, pI 
ICoN6
Dr Euan Walpole, pI, SCoT trial (AGITG)
Dr Neil Wetzig, co-pI, SNAC trial
Dr Louise Wigston (Nott), Co.23 trial (AGITG)
Associate professor Nicholas Wilcken, ANZ 
BCTG
Dr Kathryn Williams, FIELD study
professor Gary Wittert, pI, T4DM trial
Dr Desmond Yip, SCoT (AGITG)
professor John Zalcberg, AGITG chair
Rupendra N Shrestha, MSc, phD, research 
fellow
R John Simes, BSc(Med)(hons), MB BS(hons), 
MD, SM, FRACp, senior principal research 
fellow and professor
Katrin M Sjoquist, BSc(Med), MB BS, 
MClinT(R), FRACp, clinical research fellow
Martin R Stockler, MB BS(hons), MSc, FRACp, 
professor
Anna Stoklosa, BA, MA, phD, research fellow
Sonia Yip, BSc(hons), phD, senior research 
fellow
Honorary associates of the ctc
Associate professor Meera R Agar, CoGNo 
scientific advisory committee
Dr Andrew Barbour, pI, DoCToR and GAp 
trials (AGITG)
Dr Sally Baron-Hay, ANZGoG executive
Dr Andrew Berry, BooST II safety and data 
monitoring committee chair
Dr Andrew Biankin, pI, LAp07 trial (AGITG)
Dr Alex Boussioutas, Gastric trial (AGITG)
Dr Timothy Brighton, pI, ASpIRE trial
Dr Ian Campbell, pI, SNAC 2 trial
professor Christopher Christophi, AGITG 
management committee
Dr Yu Jo Chua, pI, pAN1 trial (AGITG)
professor Alan Coates, Biostatistics
professor Forrester Cockburn, BooST II trial 
Safety and Data Monitoring Committee
Ms Melinda Cruz, LIFT study
Dr Andrew Davidson, pI, NITRo trial (ALTG)
Associate professor Ian D Davis, pI, SoRCE 
trial and chair, ANZUp
Dr Andrew Dean, pI, ICoN8 trial
Dr Jayesh Desai, pI, REGISTER trial (AGITG)
professor Catherine D’Este, BooST II trial 
Safety and Data Monitoring Committee
Dr pei Ni Ding, oncology
Dr Katherine Drummond, CoGNo 
management committee
Dr John Eikelboom, co-pI, ASpIRE and 
pREDICT trials
Dr Jonathan Fawcett, co-pI, ATTACHE trial 
(AGITG)
Dr Kathryn Field, pI, CABARET trial (CoGNo)
Ms Marcia Fleet, CoGNo management 
committee
Dr Matthew Foote, CoGNo management 
committee
Dr Michael Friedlander, ANZGoG executive 
and pI, GoG182, TRIpoD, oVAR16, 
Symptom Benefit and pARAGoN trials
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staff activities
supervision of research  
degrees in 2013
Lisa Askie
Angela Carberry: phD
Anthony Keech
Jordan Fulcher: phD
Jason Harmer: phD
Kushwin Rajamani: phD
Ru-Dee Ting: phD
John simes
Claudia Dobler: phD
Jordan Fulcher: phD
Michelle cunich
Thomas Lo: phD
Val Gebski
Farnoush Noushi: phD
Anandwardhan Hardikar
Ryan Farr: phD
Wilson Wong: Mphil/phD
Michael Williams: phD
Andrzej Januszewski
Daniel Calandro: Mphil
Alicia Jenkins
paul Benitez Aguirre: phD
Daniel Calandro: Mphil
Yoon Hi Cho: phD
Ben Ma: phD
Jon Noonan: phD
Kushwin Rajamani: phD
Harris Schlen: phD
Ru-Dee Ting: phD
chee Lee
Amira Elmadahm: phD
sally Lord
Amira Elmadahm: phD
Andrew Martin
Claudia Dobler, phD
Deme Karikios, phD
Deborah schofield
Hannah Carter (Verry): phD
Deme Karikios: phD
rupendra shrestha
Hannah Carter (Verry): phD
Martin stockler
Deme Karikios: phD
Degrees awarded in 2013
Belinda Kiely: phD, The art of oncology: 
communicating survival expectancy to 
patients with cancer
Katrin Sjoquist: MClinT (R)
Anna Stoklosa: phD, The concept of 
evidence in health technology assessment
external committees
Lisa Askie
Antenatal Magnesium IpD International 
Collaboration (AMICABLE) individual 
patient data collaboration steering 
committee
Cochrane Collaboration prospective 
meta-analysis methods working group (co-
convenor) and methods editorial board
Early prevention of Childhood obesity 
(EpoCH) prospective meta-analysis 
collaboration steering committee (chair)
International Clinical Trials Registry 
platform, World Health organization 
advisory committee
International Forum for Standards for 
Research in Children sample size and 
data safety monitoring committee 
subcommittee
Meta-Analysis of preterm patients 
on Inhaled Nitric oxide (MAppINo) 
Collaboration steering group
Neonatal oxygen prospective Meta-
analysis (NeoproM) collaboration steering 
committee (chair)
NHMRC project Grant Review panel for 
Clinical Trials
perinatal Antiplatelet Review of 
International Studies (pARIS) collaboration 
steering committee, writing committee 
(chair)
PLoS ONE academic editor
prenatal Repeat Corticosteroid International 
IpD Study Group: Assessing the Effects 
Using the Best Level of Evidence (pRECISE) 
steering committee
prevention of Ventilation Induced Lung 
Injury Collaborative Group (pREVILIG) 
steering committee
Royal prince Alfred Hospital clinical trials 
(ethics) subcommittee
Systematic Reviews editorial board
Anthony Keech
CAMELLIA-TIMI 61 executive committee 
(lead investigator)
Cholesterol Treatment Trialists’ 
Collaboration (CTTC) (joint coordinator and 
convenor)
Fenofibrate and Microvascular Events 
(FAME-1) diabetes trial steering committee 
(chair)
Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) management 
committee (principal investigator and study 
chairman), and quality-of-life and cost-
effectiveness, ophthalmology, and scientific 
substudies committees
program grant investigators
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Further Cardiovascular outcomes Research 
With pCSK9 Inhibition in Subjects With 
Elevated Risk (FoURIER) executive 
committee
Long-term Intervention with pravastatin 
in Ischaemic Disease (LIpID) study 
management committee and executive
NHMRC Clinical Trials Centre management 
review committee and scientific advisory 
committee
National Health and Medical Research 
Council grant review panel
PLoS Medicine editorial board
REMoVAL trial steering committee
Royal prince Alfred Hospital clinical trials 
(ethics) subcommittee
John simes
Australia and New Zealand Breast Cancer 
Trials Group (ANZBCTG) scientific advisory 
committee
Aspirin to prevent Recurrent Venous 
Thrombo-embolism (ASpIRE) trial 
management committee (chair)
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee, 
operations executive committee, MAX trial 
management committee
Australian New Zealand Clinical Trials 
Registry (ANZCTR) policy advisory 
committee
Cholesterol Treatment Trialists Collaboration 
(CTTC) (joint coordinator)
Cooperative Trials Group for Neuro-
oncology (CoGNo) scientific advisory 
committee (deputy chair), management 
committee, operations executive
Benefits of oxygen Saturation Targeting 
(BooST) II trial management committee
Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) management 
committee, executive, and cost-
effectiveness subcommittee
Intensive Blood pressure Reduction 
for Acute Cerebral Haemorrhage Trial 
(INTERACT) safety and data monitoring 
committee (chair)
International Trials of Aspirin to prevent 
Recurrent Venous Thrombo-embolism 
(INSpIRE) steering committee
International Trials of Aspirin to prevent 
Recurrent Venous Thrombo-Embolism 
(INSpIRE) steering committee (chair)
Kanyini GAp polypill Study safety and data 
monitoring committee (chair)
Long-term Intervention with pravastatin 
in Ischaemic Disease (LIpID) management 
committee, executive, and biomarker 
subcommittee
National Health and Medical Research 
Council Academy
NHMRC Clinical Trials Centre management 
review committee and scientific advisory 
committee
Sentinel Biopsy versus Axillary Clearance 
(SNAC) trial management committee
Sydney Catalyst governing council and 
scientific advisory committee
Trials associate editor
elizabeth Barnes
Biostatistics Collaboration of Australia 
teaching committee
Cooperative Trials Group for Neuro-
oncology (CoGNo) scientific advisory 
committee
DoCToR trial management committee 
(AGITG)
outback trial management committee 
(ANZGoG)
Jenny chow
Cancer Institute NSW Neuro-oncology 
Group (NSWoG), CoGNo operations 
executive, management committee, annual 
scientific meeting organising committee, 
CoSA executive officers network and 
associated working groups
xanthi coskinas
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee, 
operational executive committee; NITRo 
trial management committee, B2p2M2 trial 
management committee, pACT in NSCLC 
trial management committee
Val Gebski
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee and 
MAX, TopGEAR, IMpACT, pAN-1, ATTACHE, 
ATTAX3, TACTIC, DoCToR, ICECREAM and 
REGISTER trial management committees 
and group statistician
Australasian Kidney Trials Network advisory 
board
Australia and New Zealand Breast Cancer 
Trials Group (ANZ BCTG) scientific advisory 
committee, GALA, LATER SoRBET and 
NeoGem trial management committees, 
and group statistician
Australian and New Zealand Urogenital 
and prostate Cancer Trials Group ANZUp 
scientific advisory committee and 
Accelerated BEp and EVERSUN trial 
management committees and group 
statistician
Australian New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee, CALYpSo trial 
management committee, pARAGoN and 
oUTBACK trial management committees, 
and group statistician
Bevacizumab use in platinum-resistant 
epithelial ovarian cancer; CLASSIC 
(Adjuvant Chemotherapy versus Surgery 
in Gastric Adenocarcinoma); GAS (Effect 
of Spinal versus General Anaesthesia in 
Neonates undergoing Hernia Repair); 
To2RpIDo (Targeted oxygenation in the 
Resuscitation of premature Infants and their 
Developmental outcome) safety and data 
monitoring committees
Biostatistics Collaboration of Australia 
steering and teaching committees
Crown princess Mary Cancer Care Centre 
(Westmead) Radiation oncology research 
committee
Laparoscopic Surgery versus Hysterectomy 
in patients with Cervical Cancer (LACC) trial 
management committee
NSW Health Central Sydney Area ethics 
committee clinical trials subcommittee
SNAC trial management committee
T4DM trial management committee
Trans Tasman Radiation oncology Group 
(TRoG) scientific committee, publications 
committee, and group statistician
Alpana Ghadge
Benefits of oxygen Saturation Targeting 
(BooST) II trial management committee
Lactoferrin Infant Feeding Trial (LIFT) 
management committee
Westmead international update 
management committee
Wendy Hague
Aspirin to prevent Recurrent Venous 
Thromboembolism (ASpIRE) management 
committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) trials operations committee and A 
La CaRT trial management committee
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) trials 
operations committee
Australian placental Transfusion Study 
(ApTS) management committee
Benefits of oxygen Saturation Targeting 
(BooST II) management committee
International Neonatal Immunotherapy 
Study (INIS) Australian and New Zealand 
management committee
International Trials of Aspirin to prevent 
Recurrent Venous Thrombo-Embolism 
(INSpIRE) steering committee
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Long-Term Intervention with pravastatin 
in Ischaemic Disease (LIpID) management 
committee
Sentinel Biopsy versus Axillary Clearance 
(SNAC) 1 and SNAC 2 trial management 
committees
Anandwardhan Hardikar
Experimental Diabetes Research special issue 
on non-coding RNAs, chief guest editor
Islet Society, Stockholm, Sweden, vice-
president
Lifestyle Interactions in Fenofibrate and the 
Epigenome (FIELD-LIFE), co-investigator
NHMRC Grant Review panel member 
for diabetes/ obesity/ stem cell panels, 
project Grant Assigners Academy member, 
Translational Research Faculty member
Non-coding RNAs in Endocrinology , editor-
in-chief
RNA-based Analysis for prediction of Islet 
Death (RApID), principal investigator
Pancreatic islet biology book editor, Springer 
series ‘Regenerative medicine’
Visiting faculty, Indian Institute of Science 
Education Research, pune, India
Alicia Jenkins
Australian Diabetes Society council member 
and treasurer
Insulin For Life Australia, Insulin for Life 
global and Insulin For Life USA board 
member
International Diabeted Federation Life For a 
Child program board member
REMoVAL study of metformin in type 1 
diabetes, co-principal investigator and 
Australian lead
TEAMSNET telehealth initiative principal 
investigator
Adrienne Kirby
Australian placental Transfusion Study 
(ApTS) management committee
Benefits of oxygen Saturation Targeting 
(BooST) II trial management committee
Combination Antibiotic Treatment for 
Methicillin Resistant Staphylococcus Aureus 
(CAMERA) trial management committee
Faculty of Medicine, University of Sydney 
postgraduate coursework committee
Improving Delivery of Secondary prophylaxis 
for Rheumatic Heart Disease trial 
management committee
International Trials of Aspirin to prevent 
Recurrent Venous Thrombo-Embolism 
(INSpIRE) steering committee
Long-Term Intervention wit pravastatin in 
Ischaemic Disease (LIpID) management 
committee Term Intervention with 
pravastatin
Randomised Trial on Surgical Treatment for 
otitis Media in children Living in Remote 
Australian Communities trial management 
committee
Royal prince Alfred Hospital clinical trials 
(ethics) subcommittee
Ann Livingstone
Cancer Institute NSW Neuro-oncology 
Group (NSWoG)
Co-operative Trials Group for Neuro-
oncology (CoGNo) operations executive 
and scientific advisory committees, 
and CABARET, CATNoN and SEED trial 
management committees
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee and 
operational executive committee.
sally Lord
protocol Advisory Committee (pASC) for 
Medical Services Advisory Committee
European Federation of Clinical Chemistry 
and Laboratory Medicine Test Evaluation 
Working Group
Andrew Martin
Australian and New Zealand Urogenital 
and prostate Cancer Trials Group (ANZUp) 
scientific advisory committee
BLoCADE safety data monitoring 
committee
oNTRAC, proCare, INTEGRATE, EpoCH, 
NeuHorizons, LIFT and EVERSUN trial 
management committees
Julie Martyn
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee, operations executive 
committee and ICoN-6, ICoN-7, poRTEC-3 
and oVAR-16 international steering 
committees and TRIpoD, Symptom Benefit, 
poRTEC-3 and outback trial management 
committees
Gynecological Cancer Intergroup (GCIG) 
harmonisation and statistics committee 
(chair)
Danielle Miller
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive committee 
and TopGEAR trial management committee
primary Care Collaborative Cancer Clinical 
Trials Group (pC4) operations team and 
scientific advisory committee
Sydney Catalyst operations committee and 
executive committee
rebecca Mister
Aspirin to prevent Recurrent Venous 
Thromboembolism (ASpIRE) management 
committee
International Trials of Aspirin to prevent 
Recurrent Venous Thrombo-Embolism 
(INSpIRE) steering committee
rachel o’connell
D-Health (a study of vitamin D and health) 
trial management committee
pARAGoN and Symptom Benefit trial 
management committees (ANZGoG)
pAN-1, TACTIC and TopGEAR trial 
management committees (AGITG)
Kate sawkins
Co-operative Trials Group for Neuro-
oncology (CoGNo) operations executive 
committee, and CABARET, CATNoN and 
SEED trial management committees
Biostatisticians, anne-sophie Veillard and rachel o’connell
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Deborah schofield
Advisory Board for pain Australia advisory 
board
Australian Research Council College of 
Experts
Garvan Institute Centre for Clinical 
Genomics, strategic advisory board
Health Workforce Australia technical 
advisory group
International Health Workforce 
Collaborative
International Journal of Microsimulation 
health editor
NSW Ministerial Advisory Committee on 
Ageing
Sydney Health policy Network steering 
committee
Westmead International Network for 
Neonatal Education and Research (WINNER 
Centre) advisory committee
Lucille sebastian
Australian placental Transfusion Study 
(ApTS) management committee and 
echocardiography substudy management 
committee
HSp 90 inhibitor study (HSp90) 
management committee
pAEAN management committee
Katrin sjoquist
Australia Asia-pacific Clinical oncology 
Research Development (ACoRD) workshop 
steering committee, alumni committee 
(chair), future faculty fellow
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee and operations 
executive committee, Symptom Benefit trial 
management committee, pARAGoN trial 
management committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee and 
operations executive committee, Upper 
GI working party, pAN1 trial management 
committee (CTC clinical lead), INTEGRATE 
trial management committee (CTC clinical 
lead) and international trial management 
group, ATTACHE, ATTAX3 and TACTIC trial 
management committees
Martin stockler
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee and 
operations executive
Australia Asia-pacific Clinical oncology 
Research Development (ACoRD) workshop 
steering committee (convenor)
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee
Australian and New Zealand Urogenital 
and prostate Cancer Trials Group (ANZUp) 
scientific advisory committee, operations 
executive and Accelerated BEp, Aprepitant, 
Chemo & Cognition and EVERSUN trial 
management committees
Cancer Council Australia national oncology 
education committee
National Health and Medical Research 
Council grant review panels for oncology
University of Sydney Faculty of Medicine 
oncology block committee (chair), EBM 
in GMp3/4 (chair), evidence-based 
medicine resource group, integrated clinical 
attachment committee and University of 
Sydney Medical program cancer planning 
committee
Burcu Vachan
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive
Australian and New Zealand Urogenital 
and prostate Cancer Trials Group (ANZUp) 
operations executive
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) operations 
executive
Australasian Lung Cancer Trials Group 
(ALTG) operations executive
Cooperative Trials Group for Neuro-
oncology (CoGNo) operations executive
Anne-sophie Veillard
ATTAX3 trial management committee
Kate Wilson
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive committee, 
scientific advisory committee and annual 
scientific meeting committee, and MAX, 
QUASAR2, pETACC6, A La CaRT, GAp, 
DoCToR, ICECREAMand ATTACHE trial 
management committees.
Nicole Wong
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive committee, 
and ATTACHE, LAp07, SCoT, ATTAX 3, 
pAN1 and TACTIC trial management 
committees
sonia yip
ARCS Australia Annual Scientific Congress 
organising committee
Australasian Gastro-Intestinal Trials 
Group (AGITG) operations executive and 
biological subcommittee, and GAp, IMpACT, 
INTEGRATE trial management committees
Australian and New Zealand Urogenital and 
prostate Group (ANZUp) scientific advisory 
committee, renal cell subcommittee, 
germ cell subcommittee, translational 
subcommittee, and EVERSUN, SoRCE
Australia New Zealand Gynaecological 
oncology Group (ANZGoG) research 
advisory committee and cervix working 
group
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee
Sydney Cancer Conference co-chair
Sydney Catalyst: Translational Cancer 
Research Centre of Central Sydney 
and Regional NSW scientific advisory 
committee, operations executive committee 
and T1 working group
regular academic teaching
Lisa Askie
Advanced systematic reviews, Master of 
Clinical Epidemiology, University of Sydney 
(co-coordinator)
Controlled clinical trials, Master of public 
Health, University of Sydney
Critical appraisal of evidence, Master of 
Clinical Trials, University of Sydney
Evidence-based medicine in the clinical 
years, University of Sydney Medical program
Anthony Keech
Royal prince Alfred Hospital cardiology 
training, and clinical tutor
Controlled clinical trials, Master of public 
Health and Master of Medicine, University 
of Sydney
Master of Clinical Trials, University of Sydney 
(coordinator)
John simes
Decision analysis, Master of public Health 
and Master of Medicine, University of 
Sydney
elizabeth Barnes
Basic sciences in oncology, NSW Health 
Education Training Institute
principles of statistical inference, 
Biostatistics Collaboration of Australia 
(coordinator)
Statistical principles and clinical trials, 
Master of Clinical Trials Research, University 
of Sydney (coordinator)
Controlled clinical trials, Master of 
public Health, University of Sydney (co-
coordinator)
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Michelle cunich
Health workforce policy analysis, Master of 
public Health, University of Sydney
Mark Donoghoe
Basic sciences in oncology, Health Education 
and Training Institute
Val Gebski
Advanced clinical trials, Biostatistics 
Collaboration of Australia (coordinator)
Basic sciences in oncology, NSW Cancer 
Council
Controlled clinical trials, Master of public 
Health and Master of Medicine, University 
of Sydney
Radiation oncology training, RACR trainees, 
Westmead Hospital, NSW Cancer Council
Wendy Hague
project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials, University 
of Sydney
Deme Karikios
Decision analysis, Master of public Health 
and Master of Medicine, University of 
Sydney
Evidence -based medicine in the clinical 
years, and oncology and palliative care, 
University of Sydney Medical program
Master of Cancer and Haematology Nursing, 
University of Sydney
Adrienne Kirby
Controlled clinical trials, Master of public 
Health and Master of Medicine, University 
of Sydney
Master of Clinical Trials, University of Sydney 
(course coordinator)
Trial design and methods, Master of Clinical 
Trials, University of Sydney (coordinator)
chee Lee
Global biomarker studies, Master of Clinical 
Trials, University of Sydney
sally Lord
Biomarker studies, Master of Clinical Trials, 
University of Sydney
Decision analysis, Master of public Health, 
University of Sydney
Kristy Mann
Advanced systematic reviews, Master of 
Clinical Epidemiology, University of Sydney
Basic sciences in oncology, NSW Cancer 
Council
Critical appraisal of evidence and 
Understanding trial methods, Master of 
Clinical Trials, University of Sydney
Andrew Martin
Decision analysis (coordinator) and 
Controlled clinical trials (coordinator), 
Master of public Health and Master of 
Medicine, University of Sydney
Interpretation of trial analyses (coordinator), 
Master of Clinical Trials, University of Sydney
rebecca Mister
project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials, University 
of Sydney
rachel o’connell
Advanced clinical trials, Biostatistics 
Collaboration of Australia (coordinator)
Advanced trial design, Master of Clinical 
Trials, University of Sydney
Deborah schofield
Health workforce policy analysis, School of 
public Health, University of Sydney
Katrin sjoquist
Evidence-based medicine, University of 
Sydney Medical program
Australia & Asia-pacific Clinical oncology 
Research Development (ACoRD) faculty
project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials, University 
of Sydney
Martin stockler
Australia & Asia-pacific Clinical oncology 
Research Development (ACoRD) convenor, 
and international steering committee 
workshop (chair)
Making sense of cancer clinical trials for 
NSW medical oncology trainees (convenor)
Clinical epidemiology for physician trainees, 
Royal prince Alfred Hospital
Evidence-based medicine in the clinical 
years, (chair and coordinator), and oncology 
and palliative care (block chair), University of 
Sydney Medical program
Medical oncology clinical training, Royal 
prince Alfred Hospital
patient-based measures, Master of 
Medicine, University of Sydney (course 
coordinator)
project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials Research, 
University of Sydney
Burcu Vachan
project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials Research, 
University of Sydney
Anne-sophie Veillard
Trial design and methods, Master of Clinical 
Trials, University of Sydney
sonia yip
Global biomarker studies, Master of 
Clinical Trials, University of Sydney (course 
coordinator)
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8. Blinman p, gainford c, donoghoe 
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